| Year |
Citation |
Score |
| 2020 |
Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F, Clark RE, Cortes JE, Deininger MW, Guilhot F, Hjorth-Hansen H, Hughes TP, Janssen JJWM, Kantarjian HM, Kim DW, et al. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia. PMID 32127639 DOI: 10.1038/S41375-020-0776-2 |
0.372 |
|
| 2019 |
Akkouh IA, Skrede S, Holmgren A, Ersland KM, Hansson L, Bahrami S, Andreassen OA, Steen VM, Djurovic S, Hughes T. Exploring lithium's transcriptional mechanisms of action in bipolar disorder: a multi-step study. Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology. PMID 31652432 DOI: 10.1038/S41386-019-0556-8 |
0.307 |
|
| 2018 |
Hiwase D, Tan P, D'Rozario J, Taper J, Powell A, Irving I, Wright M, Branford S, Yeung DT, Anderson L, Gervasio O, Levetan C, Roberts W, Solterbeck A, Traficante R, ... Hughes T, et al. Efficacy and safety of nilotinib 300 mg twice daily in patients with chronic myeloid leukemia in chronic phase who are intolerant to prior tyrosine kinase inhibitors: Results from the Phase IIIb ENESTswift study. Leukemia Research. 67: 109-115. PMID 29494928 DOI: 10.1016/J.Leukres.2018.02.013 |
0.352 |
|
| 2017 |
Nicolini FE, Basak GW, Kim DW, Olavarria E, Pinilla-Ibarz J, Apperley JF, Hughes T, Niederwieser D, Mauro MJ, Chuah C, Hochhaus A, Martinelli G, DerSarkissian M, Duh MS, McGarry LJ, et al. Overall survival with ponatinib versus allogeneic stem cell transplantation in Philadelphia chromosome-positive leukemias with the T315I mutation. Cancer. PMID 28387926 DOI: 10.1002/Cncr.30558 |
0.332 |
|
| 2017 |
Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, et al. Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 35: 175-184. PMID 28056193 DOI: 10.1200/Jco.2016.67.0893 |
0.347 |
|
| 2017 |
Banjar H, Ranasinghe D, Brown F, Adelson D, Kroger T, Leclercq T, White D, Hughes T, Chaudhri N. Modelling Predictors of Molecular Response to Frontline Imatinib for Patients with Chronic Myeloid Leukaemia. Plos One. 12: e0168947. PMID 28045960 DOI: 10.1371/Journal.Pone.0168947 |
0.352 |
|
| 2017 |
Radich J, Mahon F, Hochhaus A, Hughes T, Ailawadhi S, Lipton J, Gopalakrishna P, Fellague-Chebra R, Deng W, Acharya S, Saglio G. ENESTfreedom and ENESTop Update: Durable Treatment-Free Remission (TFR) at 96 Weeks after Nilotinib Treatment Cessation in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Clinical Lymphoma Myeloma and Leukemia. 17: S314-S315. DOI: 10.1016/J.Clml.2017.07.115 |
0.338 |
|
| 2016 |
Lipton JH, Chuah C, Guerci-Bresler A, Rosti G, Simpson D, Assouline S, Etienne G, Nicolini FE, le Coutre P, Clark RE, Stenke L, Andorsky D, Oehler V, Lustgarten S, Rivera VM, ... ... Hughes T, et al. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial. The Lancet. Oncology. PMID 27083332 DOI: 10.1016/S1470-2045(16)00080-2 |
0.373 |
|
| 2016 |
Mahon F, Hochhaus A, Hughes T, Ailawadhi S, Lipton J, Wolff J, Saglio G. Treatment-Free Remission (TFR) Following Frontline or Second-Line Nilotinib in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTfreedom and ENESTop Clinical Lymphoma Myeloma and Leukemia. 16: S64-S65. DOI: 10.1016/J.Clml.2016.07.094 |
0.344 |
|
| 2015 |
Watkins DB, Hughes TP, White DL. OCT1 and imatinib transport in CML: is it clinically relevant? Leukemia. PMID 26122430 DOI: 10.1038/Leu.2015.170 |
0.34 |
|
| 2015 |
Hughes TP, Saglio G, Quintás-Cardama A, Mauro MJ, Kim DW, Lipton JH, Bradley-Garelik MB, Ukropec J, Hochhaus A. BCR-ABL1 mutation development during first-line treatment with dasatinib or imatinib for chronic myeloid leukemia in chronic phase. Leukemia. PMID 26118315 DOI: 10.1038/Leu.2015.168 |
0.367 |
|
| 2014 |
Olshen A, Tang M, Cortes J, Gonen M, Hughes T, Branford S, Quintás-Cardama A, Michor F. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Haematologica. 99: 1701-9. PMID 25216683 DOI: 10.3324/Haematol.2013.085977 |
0.388 |
|
| 2014 |
Seymour JF, Kim DW, Rubin E, Haregewoin A, Clark J, Watson P, Hughes T, Dufva I, Jimenez JL, Mahon FX, Rousselot P, Cortes J, Martinelli G, Papayannidis C, Nagler A, et al. A phase 2 study of MK-0457 in patients with BCR-ABL T315I mutant chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia. Blood Cancer Journal. 4: e238. PMID 25127392 DOI: 10.1038/Bcj.2014.60 |
0.381 |
|
| 2013 |
Hughes T, White D. Which TKI? An embarrassment of riches for chronic myeloid leukemia patients. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013: 168-75. PMID 24319178 DOI: 10.1182/Asheducation-2013.1.168 |
0.376 |
|
| 2013 |
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre P, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DiPersio J, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, ... ... Hughes T, et al. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. The New England Journal of Medicine. 369: 1783-96. PMID 24180494 DOI: 10.1056/Nejmoa1306494 |
0.4 |
|
| 2013 |
Gallipoli P, Stobo J, Heaney N, Nicolini FE, Clark R, Wilson G, Tighe J, McLintock L, Hughes T, Michor F, Paul J, Drummond M, Holyoake TL. Safety and efficacy of pulsed imatinib with or without G-CSF versus continuous imatinib in chronic phase chronic myeloid leukaemia patients at 5 years follow-up. British Journal of Haematology. 163: 674-6. PMID 24032404 DOI: 10.1111/Bjh.12532 |
0.312 |
|
| 2013 |
Ross DM, O'Hely M, Bartley PA, Dang P, Score J, Goyne JM, Sobrinho-Simoes M, Cross NC, Melo JV, Speed TP, Hughes TP, Morley AA. Distribution of genomic breakpoints in chronic myeloid leukemia: analysis of 308 patients. Leukemia. 27: 2105-7. PMID 23588714 DOI: 10.1038/Leu.2013.116 |
0.32 |
|
| 2013 |
White HE, Hedges J, Bendit I, Branford S, Colomer D, Hochhaus A, Hughes T, Kamel-Reid S, Kim DW, Modur V, Müller MC, Pagnano KB, Pane F, Radich J, Cross NC, et al. Establishment and validation of analytical reference panels for the standardization of quantitative BCR-ABL1 measurements on the international scale. Clinical Chemistry. 59: 938-48. PMID 23471097 DOI: 10.1373/Clinchem.2012.196477 |
0.32 |
|
| 2013 |
Giles FJ, le Coutre PD, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Novick S, Gillis K, Fan X, et al. Nilotinib in imatinib-resistant or imatinib-intolerant patients with chronic myeloid leukemia in chronic phase: 48-month follow-up results of a phase II study. Leukemia. 27: 107-12. PMID 22763385 DOI: 10.1038/Leu.2012.181 |
0.392 |
|
| 2012 |
Cortes J, Goldman JM, Hughes T. Current issues in chronic myeloid leukemia: monitoring, resistance, and functional cure. Journal of the National Comprehensive Cancer Network : Jnccn. 10: S1-S13. PMID 23055247 DOI: 10.6004/Jnccn.2012.0184 |
0.371 |
|
| 2012 |
Mauro MJ, Cortes JE, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, ... ... Hughes T, et al. Multivariate Analyses of the Clinical and Molecular Parameters Associated with Efficacy and Safety in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Treated with Ponatinib in the PACE Trial Blood. 120: 3747-3747. DOI: 10.1182/Blood.V120.21.3747.3747 |
0.331 |
|
| 2012 |
Branford S, Ross D, Prime J, Field C, Altamura H, Yeoman A, Georgievski J, Phillis S, Jamison BA, Sullivan B, Yeung DT, Hughes T. Early Molecular Response and Female Sex Strongly Predict Achievement of Stable Undetectable BCR-ABL1, a Criterion for Imatinib Discontinuation in Patients with CML Blood. 120: 165-165. DOI: 10.1182/Blood.V120.21.165.165 |
0.379 |
|
| 2012 |
Cortes JE, Kim D, Pinilla-Ibarz J, Coutre Pl, Paquette R, Chuah C, Nicolini FE, Apperley J, Khoury HJ, Talpaz M, DiPersio JF, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, ... ... Hughes T, et al. A Pivotal Phase 2 Trial of Ponatinib in Patients with Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ALL) Resistant or Intolerant to Dasatinib or Nilotinib, or with the T315I BCR-ABL Mutation: 12-Month Follow-up of the PACE Trial Blood. 120: 163-163. DOI: 10.1182/Blood.V120.21.163.163 |
0.354 |
|
| 2011 |
Engler JR, Hughes TP, White DL. OCT-1 as a determinant of response to antileukemic treatment. Clinical Pharmacology and Therapeutics. 89: 608-11. PMID 21346750 DOI: 10.1038/Clpt.2011.12 |
0.389 |
|
| 2011 |
Cortes J, Hochhaus A, Hughes T, Kantarjian H. Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 524-31. PMID 21220597 DOI: 10.1200/Jco.2010.31.3619 |
0.342 |
|
| 2010 |
White HE, Matejtschuk P, Rigsby P, Gabert J, Lin F, Lynn Wang Y, Branford S, Müller MC, Beaufils N, Beillard E, Colomer D, Dvorakova D, Ehrencrona H, Goh HG, El Housni H, ... ... Hughes T, et al. Establishment of the first World Health Organization International Genetic Reference Panel for quantitation of BCR-ABL mRNA. Blood. 116: e111-7. PMID 20720184 DOI: 10.1182/Blood-2010-06-291641 |
0.304 |
|
| 2010 |
Bartley PA, Ross DM, Latham S, Martin-Harris MH, Budgen B, Wilczek V, Branford S, Hughes TP, Morley AA. Sensitive detection and quantification of minimal residual disease in chronic myeloid leukaemia using nested quantitative PCR for BCR-ABL DNA. International Journal of Laboratory Hematology. 32: e222-8. PMID 20491997 DOI: 10.1111/J.1751-553X.2010.01236.X |
0.318 |
|
| 2010 |
Osborn M, Hughes T. Managing imatinib resistance in chronic myeloid leukaemia Current Opinion in Hematology. 17: 97-103. PMID 20061946 DOI: 10.1097/Moh.0B013E3283366Bcb |
0.385 |
|
| 2010 |
Parker WT, Ho M, Lawrence RM, Irwin DL, Scott HS, Hughes T, Branford S. Detection of Low Level Nilotinib or Dasatinib Resistant BCR-ABL Mutations by Mass Spectrometry In CML Patients Who Fail Imatinib Is Highly Predictive of Their Subsequent Clonal Expansion When Treated with the Drug for Which Their Mutation Confers Resistance Blood. 116: 891-891. DOI: 10.1182/Blood.V116.21.891.891 |
0.316 |
|
| 2010 |
White DL, Saunders V, Frede A, GrootObbink K, Slader C, Yeung DT, Osborn M, Mills AK, Grigg A, Hughes T. Early Switching From Imatinib to Nilotinib In CML Patients Failing to Achieve Early Molecular Targets May Not Be An Effective Approach In Patients with Very Low OCT-1 Activity: A TIDEL II Sub-Study Blood. 116: 356-356. DOI: 10.1182/Blood.V116.21.356.356 |
0.381 |
|
| 2010 |
Kim D, Kim D, Kim S, Goh H, Pane F, Hughes T, Radich JP, Lin P, Saglio G, Branford S, Martinelli G, Soverini S, Hochhaus A. Mutation Analysis of BCR-ABL Tyrosine Kinase Domain In New Chronic Phase-Chronic Myeloid Leukemia Patients with Suboptimal Response or Treatment Failure From Imatinib Treatment. Blood. 116: 3441-3441. DOI: 10.1182/Blood.V116.21.3441.3441 |
0.379 |
|
| 2010 |
Tang C, Schafranek L, Watkins D, Parker WT, Prime J, White DL, Hughes T. Modelling of TKI Resistance In CML Cell Lines: Kinase Domain Mutations Usually Arise In the Setting of BCR-ABL Overexpression. Blood. 116: 3383-3383. DOI: 10.1182/Blood.V116.21.3383.3383 |
0.305 |
|
| 2010 |
White DL, Saunders V, Andrew M, Rofe A, Slader C, Yeung DT, Osborn M, Mills AK, Grigg A, Hughes T. Imatinib PK: Observations From the TIDEL II Study Blood. 116: 2288-2288. DOI: 10.1182/Blood.V116.21.2288.2288 |
0.314 |
|
| 2010 |
Morley AA, Bartley P, Ross D, Latham S, Budgen B, Branford S, Hughes T. Towards DNA-Based Monitoring of Therapy In Chronic Myeloid Leukemia Blood. 116: 2284-2284. DOI: 10.1182/Blood.V116.21.2284.2284 |
0.342 |
|
| 2010 |
Yeung DT, Osborn M, White DL, Branford S, Haswell L, Slader C, Issa S, Hiwase DK, Hertzberg MS, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Forsyth CJ, Ross DM, ... ... Hughes T, et al. Selective Escalation of Imatinib Therapy and Early Switching to Nilotinib In De Novo Chronic Phase CML Patients: Interim Results From the TIDEL-II Trial Blood. 116: 209-209. DOI: 10.1182/Blood.V116.21.209.209 |
0.336 |
|
| 2010 |
Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes T, Larson RA. Erratum: Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia(Leukemia (2009) 23 (1054-1061) DOI: 10.1038/leu.2009.38) Leukemia. 24. DOI: 10.1038/Leu.2010.71 |
0.346 |
|
| 2009 |
Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 6041-51. PMID 19884523 DOI: 10.1200/Jco.2009.25.0779 |
0.307 |
|
| 2009 |
Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4204-10. PMID 19652056 DOI: 10.1200/Jco.2009.21.8230 |
0.396 |
|
| 2009 |
Hughes T, Hochhaus A. Clinical strategies to achieve an early and successful response to tyrosine kinase inhibitor therapy. Seminars in Hematology. 46: S11-5. PMID 19621544 DOI: 10.1053/J.Seminhematol.2009.01.008 |
0.333 |
|
| 2009 |
Kantarjian H, Pasquini R, Lévy V, Jootar S, Holowiecki J, Hamerschlak N, Hughes T, Bleickardt E, Dejardin D, Cortes J, Shah NP. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R). Cancer. 115: 4136-47. PMID 19536906 DOI: 10.1002/Cncr.24504 |
0.33 |
|
| 2009 |
Tojo A, Usuki K, Urabe A, Maeda Y, Kobayashi Y, Jinnai I, Ohyashiki K, Nishimura M, Kawaguchi T, Tanaka H, Miyamura K, Miyazaki Y, Hughes T, Branford S, Okamoto S, et al. A Phase I/II study of nilotinib in Japanese patients with imatinib-resistant or -intolerant Ph+ CML or relapsed/refractory Ph+ ALL. International Journal of Hematology. 89: 679-688. PMID 19449194 DOI: 10.1007/S12185-009-0327-0 |
0.371 |
|
| 2009 |
Drummond MW, Heaney N, Kaeda J, Nicolini FE, Clark RE, Wilson G, Shepherd P, Tighe J, McLintock L, Hughes T, Holyoake TL. A pilot study of continuous imatinib vs pulsed imatinib with or without G-CSF in CML patients who have achieved a complete cytogenetic response. Leukemia. 23: 1199-1201. PMID 19262595 DOI: 10.1038/Leu.2009.43 |
0.302 |
|
| 2009 |
White DL, Saunders VA, Frede A, Dang P, Zrim S, Osborn MP, Manley P, Hughes T. The Functional Activity of the OCT-1 Protein Is Predictive of Molecular Response and Survival in CP-CML Patients Treated with Imatinib: A 5 Year Update of the TIDEL Trial. Blood. 114: 507-507. DOI: 10.1182/Blood.V114.22.507.507 |
0.385 |
|
| 2009 |
Branford S, Hochhaus A, Mueller M, Bahceci E, Ploughman L, Mukhopadhyay J, Hughes T. Analysis of Molecular Data and the Emergence of Mutations for Chronic-Phase Chronic Myelogenous Leukemia (CML-CP) Patients Treated with Dasatinib After Imatinib Failure. Blood. 114: 3282-3282. DOI: 10.1182/Blood.V114.22.3282.3282 |
0.331 |
|
| 2009 |
Hiwase DK, White DL, Powell JA, Saunders VA, Zrim S, Frede A, Guthridge M, D'Andrea R, To LB, Melo JV, Kumar S, Hughes T. Blocking of Cytokine Survival Signals along with Intense Bcr-Abl Kinase Inhibition May Eradicate CML Progenitor Cells. Blood. 114: 3250-3250. DOI: 10.1182/Blood.V114.22.3250.3250 |
0.313 |
|
| 2009 |
Esposito N, Quintarelli C, Colavita I, Izzo B, Peluso AL, Ruoppolo M, Vecchio LD, Russo D, Branford S, Iacobucci I, Thornquist M, Barnett M, Melo J, Saglio G, Radich J, ... ... Hughes T, et al. Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph+ Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients. Blood. 114: 2212-2212. DOI: 10.1182/Blood.V114.22.2212.2212 |
0.422 |
|
| 2008 |
Hughes T, Liberles DA. Whole-genome duplications in the ancestral vertebrate are detectable in the distribution of gene family sizes of tetrapod species. Journal of Molecular Evolution. 67: 343-57. PMID 18815825 DOI: 10.1007/S00239-008-9145-X |
0.562 |
|
| 2008 |
Branford S, Fletcher L, Cross NC, Müller MC, Hochhaus A, Kim DW, Radich JP, Saglio G, Pane F, Kamel-Reid S, Wang YL, Press RD, Lynch K, Rudzki Z, Goldman JM, ... Hughes T, et al. Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials. Blood. 112: 3330-8. PMID 18684859 DOI: 10.1182/Blood-2008-04-150680 |
0.32 |
|
| 2008 |
Shah NP, Kantarjian HM, Kim DW, Réa D, Dorlhiac-Llacer PE, Milone JH, Vela-Ojeda J, Silver RT, Khoury HJ, Charbonnier A, Khoroshko N, Paquette RL, Deininger M, Collins RH, Otero I, ... Hughes T, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 26: 3204-12. PMID 18541900 DOI: 10.1200/Jco.2007.14.9260 |
0.331 |
|
| 2008 |
Hochhaus A, Baccarani M, Deininger M, Apperley JF, Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes F, Silver RT, Niederwieser D, Stone RM, Dombret H, Larson RA, Roy L, ... Hughes T, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 22: 1200-6. PMID 18401416 DOI: 10.1038/Leu.2008.84 |
0.39 |
|
| 2008 |
Hughes T, Liberles DA. The power-law distribution of gene family size is driven by the pseudogenisation rate's heterogeneity between gene families. Gene. 414: 85-94. PMID 18378100 DOI: 10.1016/J.Gene.2008.02.014 |
0.543 |
|
| 2008 |
Giles FJ, DeAngelo DJ, Baccarani M, Deininger M, Guilhot F, Hughes T, Mauro M, Radich J, Ottmann O, Cortes J. Optimizing Outcomes for Patients With Advanced Disease in Chronic Myelogenous Leukemia Seminars in Oncology. 35. PMID 18346528 DOI: 10.1053/J.Seminoncol.2007.12.002 |
0.412 |
|
| 2008 |
le Coutre P, Ottmann OG, Giles F, Kim DW, Cortes J, Gattermann N, Apperley JF, Larson RA, Abruzzese E, O'Brien SG, Kuliczkowski K, Hochhaus A, Mahon FX, Saglio G, Gobbi M, ... ... Hughes T, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 111: 1834-9. PMID 18048643 DOI: 10.1182/Blood-2007-04-083196 |
0.371 |
|
| 2008 |
Saglio G, Radich J, Kim D, Martinelli G, Branford S, Mueller M, Soverini S, Shou Y, Hochhaus A, Hughes T. Response to nilotinib in chronic myelogenous leukemia patients in chronic phase (CML-CP) according to BCR-ABL mutations at baseline #7060 Journal of Clinical Oncology. 26: 7060-7060. DOI: 10.1200/Jco.2008.26.15_Suppl.7060 |
0.371 |
|
| 2008 |
Hochhaus A, Mueller M, Cortes JE, Kim D, Matlob Y, Ploughman L, Hughes T. Dasatinib efficacy by dosing schedule across individual baseline BCR-ABL mutations in chronic phase chronic myelogenous leukemia (CML-CP) after imatinib failure Journal of Clinical Oncology. 26: 7014-7014. DOI: 10.1200/Jco.2008.26.15_Suppl.7014 |
0.323 |
|
| 2008 |
Branford S, Lawrence R, Fletcher L, Field C, Rudzki Z, Hughes T. The Initial Molecular Response of Chronic Phase CML Patients Treated with Second Generation ABL Inhibitor Therapy after Imatinib Failure Can Predict Inadequate Response and Provide Indications for Rational Mutation Screening Blood. 112: 331-331. DOI: 10.1182/Blood.V112.11.331.331 |
0.331 |
|
| 2008 |
White DL, Saunders VA, Dang P, Frede A, Eadie L, Soverini S, Quarantelli F, Lin P, Thornquist M, Kim D, Pane F, Martinelli G, Radich J, Kalebic T, Saglio G, ... Hughes T, et al. CML Patients with Low OCT-1 Activity Achieve Better Molecular Responses on High Dose Imatinib Than on Standard Dose. Those with High OCT-1 Activity Have Excellent Responses on Either Dose: A TOPS Correlative Study Blood. 112: 3187-3187. DOI: 10.1182/Blood.V112.11.3187.3187 |
0.345 |
|
| 2008 |
Esposito N, Colavita I, Quarantelli F, Izzo B, Luciano L, Vecchio LD, Hughes T, Radich J, Russo D, Soverini S, Iacobucci I, Martinelli G, Saglio G, Melo J, Ruoppolo M, et al. A decreased Level of Shp1 provides an additive survival advantage to the Ph+ Cells of CML Patients and may account for Resistance to Imatinib Treatment Blood. 112: 3186-3186. DOI: 10.1182/Blood.V112.11.3186.3186 |
0.356 |
|
| 2008 |
Morley AA, Bartley P, Ross DM, Latham S, Martin-Harris H, Budgen B, Wilczek V, Branford S, Hughes T. DNA-Based Monitoring of Minimal Residual Disease(MRD) in Chronic Myeloid Leukemia(CML). Blood. 112: 1111-1111. DOI: 10.1182/Blood.V112.11.1111.1111 |
0.307 |
|
| 2008 |
Esposito N, Quarantelli F, Luciano L, Izzo B, Peluso AL, Picardi M, Branford S, White DL, Hughes T, Radich J, Soverini S, Iacobucci I, Saglio G, Kalebic T, Thornquist M, et al. The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial. Blood. 112: 1106-1106. DOI: 10.1182/Blood.V112.11.1106.1106 |
0.394 |
|
| 2008 |
Ross DDM, Grigg A, Schwarer A, Arthur C, Loftus K, Mills AK, Filshie R, Columbus R, Reynolds J, Seymour JF, Branford S, Hughes T. The Majority of Chronic Myeloid Leukaemia Patients Who Cease Imatinib after Achieving a Sustained Complete Molecular Response (CMR) Remain in CMR, and Any Relapses Occur Early. Blood. 112: 1102-1102. DOI: 10.1182/Blood.V112.11.1102.1102 |
0.392 |
|
| 2007 |
Branford S, Seymour JF, Grigg A, Arthur C, Rudzki Z, Lynch K, Hughes T. BCR-ABL messenger RNA levels continue to decline in patients with chronic phase chronic myeloid leukemia treated with imatinib for more than 5 years and approximately half of all first-line treated patients have stable undetectable BCR-ABL using strict sensitivity criteria. Clinical Cancer Research. 13: 7080-7085. PMID 18056186 DOI: 10.1158/1078-0432.Ccr-07-0844 |
0.391 |
|
| 2007 |
Hughes T, Liberles DA. The pattern of evolution of smaller-scale gene duplicates in mammalian genomes is more consistent with neo- than subfunctionalisation. Journal of Molecular Evolution. 65: 574-88. PMID 17957399 DOI: 10.1007/S00239-007-9041-9 |
0.561 |
|
| 2007 |
White D, Saunders V, Grigg A, Arthur C, Filshie R, Leahy MF, Lynch K, To LB, Hughes T. Measurement of in vivo BCR-ABL kinase inhibition to monitor imatinib-induced target blockade and predict response in chronic myeloid leukemia. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 25: 4445-51. PMID 17906206 DOI: 10.1200/Jco.2006.09.9499 |
0.375 |
|
| 2007 |
White DL, Saunders VA, Dang P, Engler J, Venables A, Zrim S, Zannettino A, Lynch K, Manley PW, Hughes T. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Blood. 110: 4064-72. PMID 17761829 DOI: 10.1182/Blood-2007-06-093617 |
0.34 |
|
| 2007 |
Branford S, Hughes T, Milner A, Koelmeyer R, Schwarer A, Arthur C, Filshie R, Moreton S, Lynch K, Taylor K. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near‐complete cytogenetic response to interferon‐α Cancer. 110: 801-808. PMID 17607681 DOI: 10.1002/Cncr.22842 |
0.362 |
|
| 2007 |
Hughes T, Ekman D, Ardawatia H, Elofsson A, Liberles DA. Evaluating dosage compensation as a cause of duplicate gene retention in Paramecium tetraurelia. Genome Biology. 8: 213. PMID 17521457 DOI: 10.1186/Gb-2007-8-5-213 |
0.548 |
|
| 2007 |
Kantarjian H, Pasquini R, Hamerschlak N, Rousselot P, Holowiecki J, Jootar S, Robak T, Khoroshko N, Masszi T, Skotnicki A, Hellmann A, Zaritsky A, Golenkov A, Radich J, Hughes T, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 109: 5143-50. PMID 17317857 DOI: 10.1182/Blood-2006-11-056028 |
0.36 |
|
| 2007 |
Mueller MC, Branford S, Radich J, Kim DW, Martinelli G, Saglio G, Hughes T, Shou Y, Weitzman A, Baccarani M, Hochhaus A. Response dynamics to nilotinib depend on the type of BCR-ABL mutations in patients with chronic myelogenous leukemia (CML) after imatinib failure Journal of Clinical Oncology. 25: 7024-7024. DOI: 10.1200/Jco.2007.25.18_Suppl.7024 |
0.353 |
|
| 2007 |
Hochhaus A, Branford S, Radich J, Mueller MC, Shah N, Erben P, Ernst T, Acevedo M, Nicaise C, Hughes T. Efficacy of dasatinib in chronic phase chronic myelogenous leukemia patients after imatinib failure according to baseline BCR- ABL mutations Journal of Clinical Oncology. 25: 7023-7023. DOI: 10.1200/Jco.2007.25.18_Suppl.7023 |
0.348 |
|
| 2007 |
Stone RM, Kantarjian HM, Baccarani M, Lipton JH, Hughes T, Ezzeddine R, Bleickardt E, Hochhaus A. Efficacy of Dasatinib in Patients with Chronic-Phase Chronic Myelogenous Leukemia with Resistance or Intolerance to Imatinib: 2-Year Follow-Up Data from START-C (CA180-013). Blood. 110: 734-734. DOI: 10.1182/Blood.V110.11.734.734 |
0.402 |
|
| 2007 |
Hughes T, Saglio G, Martinelli G, Kim D, Soverini S, Mueller M, Haque A, Gallagher N, Shou Y, Radich J, Branford S, Hochhaus A. Responses and Disease Progression in CML-CP Patients Treated with Nilotinib after Imatinib Failure Appear To Be Affected by the BCR-ABL Mutation Status and Types. Blood. 110: 320-320. DOI: 10.1182/Blood.V110.11.320.320 |
0.308 |
|
| 2007 |
Morley A, Bartley P, Martin-Harris H, Latham S, Ross D, Hughes T. DNA-Based Measurement of BCR-ABL in Chronic Myeloid Leukemia (CML). Blood. 110: 2946-2946. DOI: 10.1182/Blood.V110.11.2946.2946 |
0.325 |
|
| 2007 |
Saglio G, Kim D, Hochhaus A, Soverini S, Erben P, Branford S, Haque A, Gallagher N, Shou Y, Hughes T, Martinelli G, Radich J. Correlation of Clinical Response to Nilotinib with BCR-ABL Mutation Status in Advanced Phase Chronic Myelogenous Leukemia (CML-AP) Patients with Imatinib-Resistance or Intolerance. Blood. 110: 1940-1940. DOI: 10.1182/Blood.V110.11.1940.1940 |
0.31 |
|
| 2007 |
Heaney N, Drummond M, Kaeda J, Nicolini F, Clark R, Wilson G, Shepherd P, Tighe J, McLintock L, Hughes T, Holyoake TL. A Phase 3 Pilot Study of Continuous Imatinib Versus Pulsed Imatinib with or without G-CSF in Patients with Chronic Phase CML Who Have Achieved a Complete Cytogenetic Response to Imatinib. Blood. 110: 1033-1033. DOI: 10.1182/Blood.V110.11.1033.1033 |
0.358 |
|
| 2007 |
Branford S, Fletcher L, Cross NC, Hochhaus A, Mueller MC, Kim D, Radich J, Saglio G, Pane F, Lynch K, Goldman JM, Hughes T. Validation of the International Scale for Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors. Blood. 110: 1013-1013. DOI: 10.1182/Blood.V110.11.1013.1013 |
0.3 |
|
| 2007 |
Hughes T, Branford S. Ph+ ALL: resistance seeds sown early Blood. 110: 472-472. DOI: 10.1182/Blood-2007-04-085274 |
0.319 |
|
| 2006 |
Druker BJ, Guilhot F, O'Brien SG, Gathmann I, Kantarjian H, Gattermann N, Deininger MW, Silver RT, Goldman JM, Stone RM, Cervantes F, Hochhaus A, Powell BL, Gabrilove JL, Rousselot P, ... ... Hughes T, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. The New England Journal of Medicine. 355: 2408-17. PMID 17151364 DOI: 10.1056/Nejmoa062867 |
0.369 |
|
| 2006 |
Hughes T. ABL kinase inhibitor therapy for CML: baseline assessments and response monitoring Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 211-218. PMID 17124063 DOI: 10.1182/Asheducation-2006.1.211 |
0.399 |
|
| 2006 |
Branford S, Cross NC, Hochhaus A, Radich J, Saglio G, Kaeda J, Goldman J, Hughes T. Rationale for the recommendations for harmonizing current methodology for detecting BCR-ABL transcripts in patients with chronic myeloid leukaemia. Leukemia. 20: 1925-30. PMID 16990771 DOI: 10.1038/Sj.Leu.2404388 |
0.351 |
|
| 2006 |
Grigg A, Hughes T. Role of allogeneic stem cell transplantation for adult chronic myeloid leukemia in the imatinib era. Biology of Blood and Marrow Transplantation. 12: 795-807. PMID 16864049 DOI: 10.1016/J.Bbmt.2006.03.012 |
0.363 |
|
| 2006 |
Baccarani M, Saglio G, Goldman J, Hochhaus A, Simonsson B, Appelbaum F, Apperley J, Cervantes F, Cortes J, Deininger M, Gratwohl A, Guilhot F, Horowitz M, Hughes T, Kantarjian H, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood. 108: 1809-20. PMID 16709930 DOI: 10.1182/Blood-2006-02-005686 |
0.368 |
|
| 2006 |
Branford S, Hughes T. Detection of BCR-ABL mutations and resistance to imatinib mesylate. Methods in Molecular Medicine. 125: 93-106. PMID 16502579 DOI: 10.1385/1-59745-017-0:93 |
0.346 |
|
| 2006 |
Branford S, Hughes T. Diagnosis and Monitoring of Chronic Myeloid Leukemia by Qualitative and Quantitative RT-PCR Methods in Molecular Medicine. 125: 69-92. PMID 16502578 DOI: 10.1385/1-59745-017-0:69 |
0.35 |
|
| 2006 |
Ross DM, Branford S, Moore S, Hughes TP. Limited clinical value of regular bone marrow cytogenetic analysis in imatinib-treated chronic phase CML patients monitored by RQ-PCR for BCR-ABL Leukemia. 20: 664-670. PMID 16482210 DOI: 10.1038/Sj.Leu.2404139 |
0.39 |
|
| 2006 |
Hughes T, Branford S. Molecular monitoring of BCR-ABL as a guide to clinical management in chronic myeloid leukaemia. Blood Reviews. 20: 29-41. PMID 16426942 DOI: 10.1016/J.Blre.2005.01.008 |
0.391 |
|
| 2006 |
Giles FJ, Larson R, Coutre PL, Baccarani M, Tavorath R, Alland L, Kantarjian HM, Hughes T, Ottmann O. A phase II study of AMN107, a novel inhibitor of Bcr-Abl, administered to imatinib-resistant or intolerant patients (pts) with Ph+ chronic myelogenous leukemia (CML) in blast crisis (BC) or relapsed/refractory Ph+ acute lymphoblastic leukemia (ALL) Journal of Clinical Oncology. 24: 6536-6536. DOI: 10.1200/Jco.2006.24.18_Suppl.6536 |
0.349 |
|
| 2006 |
Hochhaus A, Erben P, Branford S, Radich J, Kim DW, Martinelli G, Saglio G, Mueller MC, Hoffmann J, Palandri F, Soverini S, Hughes T, Shou Y, Weitzman A, Baccarani M. Hematologic and Cytogenetic Response Dynamics to Nilotinib (AMN107) Depend on the Type of BCR-ABL Mutations in Patients with Chronic Myelogeneous Leukemia (CML) after Imatinib Failure. Blood. 108: 749-749. DOI: 10.1182/Blood.V108.11.749.749 |
0.342 |
|
| 2006 |
White D, Saunders V, Dang P, Venables A, Zrim S, Reynolds J, Quinn S, Zannettino A, Hughes T. Molecular Response to Imatinib Is Dependent on Dose in CML Patients with Low OCT-1 Influx Activity. Patients with High Activity May Respond Equally Well to Standard or Increased Dose Imatinib. Blood. 108: 738-738. DOI: 10.1182/Blood.V108.11.738.738 |
0.332 |
|
| 2006 |
Branford S, Seymour JF, Grigg A, Arthur C, Lynch K, Hughes T. Increasing Frequency and Marked Stability of Complete Molecular Response Is Observed in Imatinib-Treated CML Patients with Long-Term Follow Up. Blood. 108: 430-430. DOI: 10.1182/Blood.V108.11.430.430 |
0.393 |
|
| 2006 |
Hochhaus A, Ottmann OG, Lauber S, Hughes T, Verhoef G, Schwarer AP, Gratwohl A, Rafferty T, Resta D, Gattermann N. A Phase II Study of Nilotinib, a Novel Inhibitor of c-Kit, PDGFR, and Bcr-Abl, Administered to Patients with Systemic Mastocytosis. Blood. 108: 2703-2703. DOI: 10.1182/Blood.V108.11.2703.2703 |
0.374 |
|
| 2006 |
Seymour JF, Grigg A, Reynolds J, Schwarer AP, Hermann R, Taylor KM, Bradstock KF, Mills AK, Koelmeyer R, Lynch K, Hughes T. Two Year Data from a Prospective Safety Study Analyzing the Consequences of Imatinib Mesylate Inhibition of Sensitive Kinases Other Than bcr-abl in Patients with Previously Untreated Chronic Phase CML. Blood. 108: 2147-2147. DOI: 10.1182/Blood.V108.11.2147.2147 |
0.306 |
|
| 2006 |
White D, Dang P, Venables A, Saunders V, Zrim S, Zannettino A, Diamond P, Quinn S, To LB, Hughes T. ABCB1 Overexpression May Predispose Imatinib Treated CML Patients to the Development of Abl Kinase Domain Mutations, and May Be an Important Contributor to Acquired Resistance. Blood. 108: 2144-2144. DOI: 10.1182/Blood.V108.11.2144.2144 |
0.384 |
|
| 2006 |
Branford S, Hughes T, Stylian S, Schwarer AP, Arthur C, Filshie R, Moreton S, Rodwell R, Guzzo-Pernell N, Taylor D, Larson J, Koelmayer R, Milner A, Lynch K, Taylor KM. Significant Reduction of BCR-ABL Transcripts after Switching to Imatinib Therapy in Patients with CML and Complete or Near-Complete Cytogenetic Responses to Interferon-Alpha (IFN). Blood. 108: 2142-2142. DOI: 10.1182/Blood.V108.11.2142.2142 |
0.377 |
|
| 2006 |
Kaeda J, Hochhaus A, Radich J, Branford S, So C, Gathmann I, Wehrle E, Goldman J, Hughes T. Patients with Chronic Phase CML in the IRIS Study Who Receive Imatinib Mesylate (IM) 2nd Line after Prior IFN/Ara-C Have Sustained Complete Cytogenetic and Major Molecular Response Rates Similar to 1st Line IM Patients. Blood. 108: 2139-2139. DOI: 10.1182/Blood.V108.11.2139.2139 |
0.304 |
|
| 2006 |
Shah N, Pasquini R, Rousselot P, Jootar S, Holowiecki J, Countouriotis A, Dejardin D, Hughes T, Druker BJ. Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study. Blood. 108: 167-167. DOI: 10.1182/Blood.V108.11.167.167 |
0.32 |
|
| 2005 |
White D, Saunders V, Lyons AB, Branford S, Grigg A, To LB, Hughes T. In vitro sensitivity to imatinib-induced inhibition of ABL kinase activity is predictive of molecular response in patients with de novo CML. Blood. 106: 2520-6. PMID 15956284 DOI: 10.1182/Blood-2005-03-1103 |
0.383 |
|
| 2005 |
Branford S, Hughes T, Nicoll J, Paquette R, Bleickardt E, Sawyers C, Shah N. Major Molecular Responses to Dasatinib (BMS-354825) Are Observed in Imatinib-Resistant Late Stage Chronic and Advanced CML Patients: Impact and Fate of Imatinib-Resistant Clones in Dasatinib-Treated Patients. Blood. 106: 437-437. DOI: 10.1182/Blood.V106.11.437.437 |
0.39 |
|
| 2005 |
Oehler V, Branford S, Pogosova-Agadjanyan E, Shah N, Sawyers C, Mao M, Linsley P, Hughes T, Radich J. Gene Expression Signatures Associated with Treatment and Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients. Blood. 106: 433-433. DOI: 10.1182/Blood.V106.11.433.433 |
0.384 |
|
| 2005 |
Branford S, Rudzki Z, Lynch K, Hughes T. Pre-Imatinib Factors Can Be Used To Define the Risk of BCR-ABL Mutations for Patients with CML in Chronic Phase and Identify a Minority Who Should Have Regular Mutation Screening. Blood. 106: 1079-1079. DOI: 10.1182/Blood.V106.11.1079.1079 |
0.35 |
|
| 2004 |
Mollee P, Arthur C, Hughes T, Januszewicz H, Grigg A, Bradstock K, Wolf M, Gibson J, Schwarer AP, Spencer A, Browett P, Hawkins T, Seldon M, Herrmann R, Watson A, et al. Interferon-α-2b and oral cytarabine ocfosfate for newly diagnosed chronic myeloid leukaemia Annals of Oncology. 15: 1810-1815. PMID 15550587 DOI: 10.1093/Annonc/Mdh468 |
0.304 |
|
| 2004 |
Faderl S, Hochhaus A, Hughes T. Monitoring of minimal residual disease in chronic myeloid leukemia. Hematology/Oncology Clinics of North America. 18: 657-70, ix-x. PMID 15271398 DOI: 10.1016/J.Hoc.2004.03.010 |
0.338 |
|
| 2004 |
Hochhaus A, Hughes T. Clinical resistance to imatinib: mechanisms and implications. Hematology/Oncology Clinics of North America. 18: 641-56, ix. PMID 15271397 DOI: 10.1016/J.Hoc.2004.03.001 |
0.332 |
|
| 2004 |
Branford S, Rudzki Z, Parkinson I, Grigg A, Taylor K, Seymour JF, Durrant S, Browett P, Schwarer AP, Arthur C, Catalano J, Leahy MF, Filshie R, Bradstock K, Herrmann R, ... ... Hughes T, et al. Real-time quantitative PCR analysis can be used as a primary screen to identify patients with CML treated with imatinib who have BCR-ABL kinase domain mutations. Blood. 104: 2926-32. PMID 15256429 DOI: 10.1182/Blood-2004-03-1134 |
0.355 |
|
| 2004 |
Hughes T, Hyun Y, Liberles DA. Visualising very large phylogenetic trees in three dimensional hyperbolic space. Bmc Bioinformatics. 5: 48. PMID 15117420 DOI: 10.1186/1471-2105-5-48 |
0.515 |
|
| 2004 |
Ross DM, Hughes TP. Cancer treatment with kinase inhibitors: what have we learnt from imatinib? British Journal of Cancer. 90: 12-9. PMID 14710199 DOI: 10.1038/Sj.Bjc.6601507 |
0.305 |
|
| 2004 |
Seymour JF, Grigg A, Reynolds J, Matthews J, Schwarer AP, Herrmann R, Taylor KM, Hertzberg MS, Mills A, Guzzo-Pernell N, Copeman M, Lynch K, Hughes T. Imatinib’s Potential Effects on Fertility, Immunity and Pulmonary Function: A Prospective Study in Patients with Previously Untreated CML. Blood. 104: 1020-1020. DOI: 10.1182/Blood.V104.11.1020.1020 |
0.332 |
|
| 2004 |
Paschka P, Branford S, Lorentz C, Hehlmann R, Hughes T, Hochhaus A. Comparison of "Log Reduction from Median Pretherapeutic Value" vs Ratio BCR-ABL/ABL to Express the Therapeutic Response in CML Patients. Blood. 104: 1013-1013. DOI: 10.1182/Blood.V104.11.1013.1013 |
0.348 |
|
| 2004 |
Hughes T, Branford S, Reynolds J, Seymour J, Taylor K, Guzzo-Pernell N, Filshie R, Arthur C, Schwarer A, Hertzberg M, Rudzki Z, Copeman M, Lynch K, Grigg A. Higher-Dose Imatinib (600 mg/Day) with Selective Intensification in Newly Diagnosed CML Patients in Chronic Phase; Cytogenetic Response Rates at 12 Months Are Superior to IRIS. Blood. 104: 1001-1001. DOI: 10.1182/Blood.V104.11.1001.1001 |
0.341 |
|
| 2003 |
Hughes T, Branford S. Molecular monitoring of chronic myeloid leukemia. Seminars in Hematology. 40: 62-68. PMID 12783378 DOI: 10.1053/Shem.2003.50044 |
0.399 |
|
| 2003 |
O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. The New England Journal of Medicine. 348: 994-1004. PMID 12637609 DOI: 10.1056/Nejmoa022457 |
0.351 |
|
| 2003 |
Branford S, Rudzki Z, Walsh S, Parkinson I, Grigg A, Szer J, Taylor K, Herrmann R, Seymour JF, Arthur C, Joske D, Lynch K, Hughes T. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis Blood. 102: 276-283. PMID 12623848 DOI: 10.1182/Blood-2002-09-2896 |
0.352 |
|
| 2001 |
Hui CH, Bardy P, Hughes T, Horvath N, To LB. Successful salvage of RAEB/AML relapsing early post allograft with FLAG-Ida conditioned mini-allograft: a report of two cases. Clinical and Laboratory Haematology. 23: 135-8. PMID 11488854 DOI: 10.1046/J.1365-2257.2001.00359.X |
0.323 |
|
| 2000 |
Branford S, Rudzki Z, Hughes T. A novel BCR-ABL transcript (e8a2) with the insertion of an inverted sequence of ABL intron 1b in a patient with Philadelphia-positive chronic myeloid leukaemia. British Journal of Haematology. 109: 635-637. PMID 10886215 DOI: 10.1046/J.1365-2141.2000.02042.X |
0.306 |
|
| 1999 |
Branford S, Hughes T, Rudzki Z. Monitoring chronic myeloid leukaemia therapy by real-time quantitative PCR in blood is a reliable alternative to bone marrow cytogenetics British Journal of Haematology. 107: 587-599. PMID 10583264 DOI: 10.1046/J.1365-2141.1999.01749.X |
0.347 |
|
| 1999 |
Grigg AP, Szer J, Beresford J, Dodds A, Bradstock K, Durrant S, Schwarer AP, Hughes T, Herrmann R, Gibson J, Arthur C, Matthews J. Factors affecting the outcome of allogeneic bone marrow transplantation for adult patients with refractory or relapsed acute leukaemia. British Journal of Haematology. 107: 409-418. PMID 10583235 DOI: 10.1046/J.1365-2141.1999.01713.X |
0.313 |
|
| 1997 |
Lewis ID, Haylock DN, Moore S, To LB, Hughes TP. Peripheral blood is a source of BCR-ABL-negative pre-progenitors in early chronic phase chronic myeloid leukemia. Leukemia. 11: 581-7. PMID 9096699 DOI: 10.1038/Sj.Leu.2400604 |
0.308 |
|
| 1993 |
Cross NCP, Feng L, Chase A, Bungey J, Hughes T, Goldman JM. Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 82: 1929-1936. DOI: 10.1182/Blood.V82.6.1929.Bloodjournal8261929 |
0.358 |
|
| 1990 |
Morgan GJ, Hernandez A, Chan LC, Hughes T, Martiat P, Wiedemann LM. The role of alternative splicing patterns of BCR/ABL transcripts in the generation of the blast crisis of chronic myeloid leukaemia. British Journal of Haematology. 76: 33-38. PMID 2223646 DOI: 10.1111/J.1365-2141.1990.Tb07833.X |
0.352 |
|
| 1989 |
Hughes T, Economou K, Mackinnon S, Vlitos M, Arthur CK, Guo AP, Rassool F, Apperley JF, Hows J, Goldman JM. Slow evolution of chronic myeloid leukaemia relapsing after BMT with T-cell depleted donor marrow. British Journal of Haematology. 73: 462-467. PMID 2611134 DOI: 10.1111/J.1365-2141.1989.Tb00281.X |
0.353 |
|
| 1989 |
Morgan GJ, Janssen JWG, Guo AP, Wiedemann LM, Hughes T, Gow J, Goldman JM, Bartram CR. Polymerase chain reaction for detection of residual leukaemia. The Lancet. 333: 928-929. PMID 2565420 DOI: 10.1016/S0140-6736(89)92508-7 |
0.326 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2007 |
Toplin J, Fuller C, Fletcher L, Wong S, Maslak P, Cortes J, Mazanet R, Branford S, Hughes T, Galderisi C, Heinrich M, Druker B, Beillard E. An MMR Control RNA for Reliable Monitoring of BCR-ABL Transcripts in Treated CML Patients. Blood. 110: 2939-2939. DOI: 10.1182/Blood.V110.11.2939.2939 |
0.298 |
|
| 2002 |
Borg M, Hughes T, Horvath N, Rice M, Thomas AC. Renal toxicity after total body irradiation. International Journal of Radiation Oncology, Biology, Physics. 54: 1165-73. PMID 12419445 DOI: 10.1016/S0360-3016(02)03039-0 |
0.297 |
|
| 2017 |
Hughes T, Saglio G. Expert opinion on the treatment of refractory chronic phase chronic myeloid leukaemia European Oncology and Haematology. 13: 17-23. DOI: 10.17925/Eoh.2017.13.01.17 |
0.294 |
|
| 2000 |
Moore S, McDiarmid LA, Hughes TP. Stem cell factor and chronic myeloid leukemia CD34+ cells Leukemia and Lymphoma. 38: 211-220. PMID 10830729 DOI: 10.3109/10428190009087013 |
0.293 |
|
| 2015 |
Barøy T, Koster J, Strømme P, Ebberink MS, Misceo D, Ferdinandusse S, Holmgren A, Hughes T, Merckoll E, Westvik J, Woldseth B, Walter J, Wood N, Tvedt B, Stadskleiv K, et al. A novel type of rhizomelic chondrodysplasia punctata, RCDP5, is caused by loss of the PEX5 long isoform. Human Molecular Genetics. 24: 5845-54. PMID 26220973 DOI: 10.1093/Hmg/Ddv305 |
0.292 |
|
| 2000 |
Craddock C, Bardy P, Kreiter S, Johnston R, Apperley J, Marks D, Huber C, Kolbe K, Goulding R, Lawler M, Goldman J, Hughes T, Derigs G. Engraftment of T‐cell‐depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen British Journal of Haematology. 111: 797-800. DOI: 10.1111/J.1365-2141.2000.02454.X |
0.292 |
|
| 2009 |
Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, ... ... Hughes TP, et al. Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 3472-9. PMID 19487385 DOI: 10.1200/JCO.2007.14.3339 |
0.292 |
|
| 1990 |
Hughes T, Goldman JM. Improved results with PCR for chronic myeloid leukaemia. The Lancet. 336: 812-812. PMID 1976169 DOI: 10.1016/0140-6736(90)93275-T |
0.29 |
|
| 1991 |
Sensky T, Hughes T, Hirsch S. Compulsory psychiatric treatment in the community. II. A controlled study of patients whom psychiatrists would recommend for compulsory treatment in the community. British Journal of Psychiatry. 158: 799-804. PMID 1873633 DOI: 10.1192/Bjp.158.6.799 |
0.29 |
|
| 2005 |
Goldman JM, Hughes T, Radich J, Branford S, Hochhaus A, So C, Gathmann I, Wehrle E, Kaeda J. Continuing Reduction in Level of Residual Disease after 4 Years in Patients with CML in Chronic Phase Responding to First-Line Imatinib (IM) in the IRIS Study. Blood. 106: 163-163. DOI: 10.1182/Blood.V106.11.163.163 |
0.289 |
|
| 2010 |
Pasquini R, Cortes J, Kantarjian HM, Joske D, Meillon LA, Mongay L, Reynolds J, Hughes T, Kim D. A Worldwide Observational Registry Collecting Longitudinal Data on Management of Chronic Myeloid Leukemia Patients (The WORLD CML Registry) – 2nd Annual Interim Analysis Blood. 116: 2292-2292. DOI: 10.1182/Blood.V116.21.2292.2292 |
0.289 |
|
| 2008 |
Branford S, Lawrence R, Grigg A, Seymour JF, Schwarer A, Arthur C, Rudzki Z, Hughes T. Long Term Follow up of Patients with CML in Chronic Phase Treated with First-Line Imatinib Suggests That Earlier Achievement of a Major Molecular Response Leads to Greater Stability of Response. Blood. 112: 2113-2113. DOI: 10.1182/Blood.V112.11.2113.2113 |
0.288 |
|
| 2016 |
Hochhaus A, Saglio G, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre PD, Etienne G, Dorlhiac-Llacer PE, Clark RE, Flinn IW, Nakamae H, Donohue B, Deng W, Dalal D, et al. Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial. Leukemia. PMID 26837842 DOI: 10.1038/Leu.2016.5 |
0.287 |
|
| 2016 |
Talpaz M, Müller M, Baccarani M, Deininger M, Guilhot F, Hochhaus A, Hughes T, Shah N, Lustgarten S, Rivera V, Clackson T, Haluska F, Cortes J. Impact of Landmark Responses on 3-Year Outcomes in CP-CML Patients in the Ponatinib PACE Trial Clinical Lymphoma Myeloma and Leukemia. 16: S61-S62. DOI: 10.1016/J.Clml.2016.07.089 |
0.286 |
|
| 2008 |
Hughes T. Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia? Commentary Nature Clinical Practice Oncology. 5: 14-15. DOI: 10.1038/Ncponc0983 |
0.285 |
|
| 2011 |
Kantarjian HM, Giles FJ, Bhalla KN, Pinilla-Ibarz J, Larson RA, Gattermann N, Ottmann OG, Hochhaus A, Radich JP, Saglio G, Hughes TP, Martinelli G, Kim DW, Shou Y, Gallagher NJ, et al. Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results. Blood. 117: 1141-5. PMID 21098399 DOI: 10.1182/Blood-2010-03-277152 |
0.285 |
|
| 2008 |
Hui CH, Sia H, Mangos H, Horvath N, Lee H, Lewis I, Hughes T, To LB, Bardy P. Daclizumab has poor efficacy in steroid-refractory severe acute graft-versus-host disease: a single centre experience with 12 allograft patients. Bone Marrow Transplantation. 41: 409-10. PMID 18026147 DOI: 10.1038/Sj.Bmt.1705927 |
0.284 |
|
| 2012 |
Selmer KK, Gilfillan GD, Strømme P, Lyle R, Hughes T, Hjorthaug HS, Brandal K, Nakken S, Misceo D, Egeland T, Munthe LA, Braekken SK, Undlien DE. A mild form of Mucopolysaccharidosis IIIB diagnosed with targeted next-generation sequencing of linked genomic regions European Journal of Human Genetics. 20: 58-63. PMID 21712855 DOI: 10.1038/Ejhg.2011.126 |
0.283 |
|
| 2007 |
Hochhaus A, Kantarjian HM, Baccarani M, Lipton JH, Apperley JF, Druker BJ, Facon T, Goldberg SL, Cervantes F, Niederwieser D, Silver RT, Stone RM, Hughes TP, Muller MC, Ezzeddine R, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood. 109: 2303-9. PMID 17138817 DOI: 10.1182/Blood-2006-09-047266 |
0.281 |
|
| 1994 |
Orr SL, Hughes TP, Sawyers CL, Kato RM, Quan SG, Williams SP, Witte ON, Hood L. Isolation of unknown genes from human bone marrow by differential screening and single-pass cDNA sequence determination. Proceedings of the National Academy of Sciences of the United States of America. 91: 11869-73. PMID 7991548 DOI: 10.1073/Pnas.91.25.11869 |
0.28 |
|
| 2009 |
Hughes TP, Branford S. Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction. Clinical Lymphoma & Myeloma. 9: S266-71. PMID 19778851 DOI: 10.3816/CLM.2009.s.022 |
0.28 |
|
| 2013 |
Ross DM, Branford S, Seymour JF, Schwarer AP, Arthur C, Yeung DT, Dang P, Goyne JM, Slader C, Filshie RJ, Mills AK, Melo JV, White DL, Grigg AP, Hughes TP. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study. Blood. 122: 515-22. PMID 23704092 DOI: 10.1182/blood-2013-02-483750 |
0.28 |
|
| 2018 |
Hong J, Brandt N, Abdual-Rahman F, Yang AWH, Hughes TR, Gresham D. An incoherent feedforward loop facilitates adaptive tuning of gene expression. Elife. 7. PMID 29620523 DOI: 10.7554/Elife.32323 |
0.279 |
|
| 2018 |
Ross DM, Pagani IS, Shanmuganathan N, Kok CH, Seymour JF, Mills AK, Filshie RJ, Arthur CK, Dang P, Saunders VA, Braley J, Yong AS, Yeung DT, White DL, Grigg AP, ... ... Hughes TP, et al. Long-term treatment-free remission of chronic myeloid leukemia with falling levels of residual leukemic cells. Leukemia. PMID 30315232 DOI: 10.1038/s41375-018-0264-0 |
0.279 |
|
| 1991 |
Sensky T, Hughes T, Hirsch S. Compulsory psychiatric treatment in the community. I. A controlled study of compulsory community treatment with extended leave under the Mental Health Act: special characteristics of patients treated and impact of treatment. British Journal of Psychiatry. 158: 792-799. PMID 1908342 DOI: 10.1192/Bjp.158.6.792 |
0.279 |
|
| 2006 |
Hughes T, Deininger M, Hochhaus A, Branford S, Radich J, Kaeda J, Baccarani M, Cortes J, Cross NC, Druker BJ, Gabert J, Grimwade D, Hehlmann R, Kamel-Reid S, Lipton JH, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 108: 28-37. PMID 16522812 DOI: 10.1182/Blood-2006-01-0092 |
0.278 |
|
| 2000 |
Szabó F, Horvath N, Seimon S, Hughes T. Inappropriate antidiuretic hormone secretion, abdominal pain and disseminated varicella-zoster virus infection: an unusual triad in a patient 6 months post mini-allogeneic peripheral stem cell transplant for chronic myeloid leukemia Bone Marrow Transplantation. 26: 231-233. PMID 10918438 DOI: 10.1038/Sj.Bmt.1702486 |
0.276 |
|
| 2006 |
Branford S, Cross NCP, Hochhaus A, Radich J, Saglio G, Kim DW, Fletcher L, Wang YL, Higgins M, Kovalenko S, Shih L, Tang JL, Ma E, Wong M, Cortes J, ... ... Hughes T, et al. First Results from a Collaborative Initiative To Develop an International Scale for the Measurement of BCR-ABL by RQ-PCR Based on Deriving Laboratory-Specific Conversion Factors. Blood. 108: 737-737. DOI: 10.1182/Blood.V108.11.737.737 |
0.275 |
|
| 2020 |
Akkouh IA, Ueland T, Hansson L, Inderhaug E, Hughes T, Eiel Steen N, Aukrust P, Andreassen OA, Szabo A, Djurovic S. Decreased IL-1β-induced CCL20 response in human iPSC-astrocytes in schizophrenia: potential attenuating effects on recruitment of regulatory T cells. Brain, Behavior, and Immunity. PMID 32109548 DOI: 10.1016/J.Bbi.2020.02.008 |
0.275 |
|
| 2020 |
Shanmuganathan N, Pagani IS, Ross DM, Park S, Yong AS, Braley JA, Altamura HK, Hiwase DK, Yeung DT, Kim DW, Branford S, Hughes TP. Early BCR-ABL1 kinetics are predictive of subsequent achievement of treatment-free remission in chronic myeloid leukemia. Blood. PMID 32871588 DOI: 10.1182/blood.2020005514 |
0.274 |
|
| 2012 |
Gilfillan GD, Hughes T, Sheng Y, Hjorthaug HS, Straub T, Gervin K, Harris JR, Undlien DE, Lyle R. Limitations and possibilities of low cell number ChIP-seq. Bmc Genomics. 13: 645. PMID 23171294 DOI: 10.1186/1471-2164-13-645 |
0.27 |
|
| 2012 |
Hercus TR, Broughton SE, Ekert PG, Ramshaw HS, Perugini M, Grimbaldeston M, Woodcock JM, Thomas D, Pitson S, Hughes T, D'Andrea RJ, Parker MW, Lopez AF. The GM-CSF receptor family: mechanism of activation and implications for disease. Growth Factors (Chur, Switzerland). 30: 63-75. PMID 22257375 DOI: 10.3109/08977194.2011.649919 |
0.27 |
|
| 2023 |
Hochhaus A, Réa D, Boquimpani C, Minami Y, Cortes JE, Hughes TP, Apperley JF, Lomaia E, Voloshin S, Turkina A, Kim DW, Abdo A, Fogliatto LM, le Coutre P, Sasaki K, et al. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. PMID 36717654 DOI: 10.1038/s41375-023-01829-9 |
0.267 |
|
| 2018 |
Hong J, Brandt N, Abdul-Rahman F, Yang A, Hughes T, Gresham D. Author response: An incoherent feedforward loop facilitates adaptive tuning of gene expression Elife. DOI: 10.7554/Elife.32323.017 |
0.267 |
|
| 2003 |
Dewar AL, Domaschenz RM, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the in vitro development of the monocyte/macrophage lineage from normal human bone marrow progenitors Leukemia. 17: 1713-1721. PMID 12970769 DOI: 10.1038/Sj.Leu.2403071 |
0.267 |
|
| 2018 |
Yong AS, Shanmuganathan N, Hughes T. Treatment-Free Remission in CML: Selecting the Best Candidates Clinical Lymphoma, Myeloma & Leukemia. 18. DOI: 10.1016/J.Clml.2018.06.034 |
0.266 |
|
| 2020 |
Schmitz U, Shah JS, Dhungel BP, Monteuuis G, Luu PL, Petrova V, Metierre C, Nair SS, Bailey CG, Saunders VA, Turhan AG, White DL, Branford S, Clark SJ, Hughes TP, et al. Widespread Aberrant Alternative Splicing despite Molecular Remission in Chronic Myeloid Leukaemia Patients. Cancers. 12. PMID 33322625 DOI: 10.3390/cancers12123738 |
0.266 |
|
| 2013 |
Abboud C, Berman E, Cohen A, Cortes J, DeAngelo D, Deininger M, Devine S, Druker B, Fathi A, Jabbour E, Jagasia M, Kantarjian H, Khoury J, Laneuville P, Larson R, ... ... Hughes T, et al. The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts Blood. 121: 4439-4442. PMID 23620577 DOI: 10.1182/Blood-2013-03-490003 |
0.265 |
|
| 2021 |
Hughes TP, Clementino NCD, Fominykh M, Lipton JH, Turkina AG, Moiraghi EB, Nicolini FE, Takahashi N, Sacha T, Kim DW, Fellague-Chebra R, Tiwari R, Bouard C, Mahon FX. Long-term treatment-free remission in patients with chronic myeloid leukemia after second-line nilotinib: ENESTop 5-year update. Leukemia. PMID 33980976 DOI: 10.1038/s41375-021-01260-y |
0.265 |
|
| 2023 |
Pagani IS, Shanmuganathan N, Dang P, Saunders VA, Grose R, Kok CH, James J, Tolland M, Braley JA, Altamura HK, Yeung DT, Branford S, Yong AS, Hughes TP, Ross DM. Lineage-specific detection of residual disease predicts relapse in chronic myeloid leukemia patients stopping therapy. Blood. PMID 37616555 DOI: 10.1182/blood.2023021119 |
0.265 |
|
| 2009 |
Hughes TP, Branford S. Monitoring disease response to tyrosine kinase inhibitor therapy in CML. Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 477-87. PMID 20008233 DOI: 10.1182/asheducation-2009.1.477 |
0.265 |
|
| 2023 |
Radich JP, Wall M, Branford S, Campbell CD, Chaturvedi S, DeAngelo DJ, Deininger M, Guinney J, Hochhaus A, Hughes TP, Kantarjian HM, Larson RA, Li S, Maegawa R, Mishra K, et al. Molecular response in newly diagnosed chronic-phase chronic myeloid leukemia: prediction modeling and pathway analysis. Haematologica. PMID 36727397 DOI: 10.3324/haematol.2022.281878 |
0.265 |
|
| 2016 |
Parker WT, Yeung DT, Yeoman AL, Altamura HK, Jamison BA, Field CR, Hodgson JG, Lustgarten S, Rivera VM, Hughes TP, Branford S. The impact of multiple low-level BCR-ABL1 mutations on response to ponatinib. Blood. PMID 26773037 DOI: 10.1182/blood-2015-09-666214 |
0.264 |
|
| 2017 |
Wylie AA, Schoepfer J, Jahnke W, Cowan-Jacob SW, Loo A, Furet P, Marzinzik AL, Pelle X, Donovan J, Zhu W, Buonamici S, Hassan AQ, Lombardo F, Iyer V, Palmer M, ... ... Hughes TP, et al. The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1. Nature. PMID 28329763 DOI: 10.1038/Nature21702 |
0.263 |
|
| 2007 |
Hughes T, Branford S, Goldman JM. Response: Reliability of PCR for BCR-ABL transcripts Blood. 109: 2263-2264. DOI: 10.1182/Blood-2006-11-054775 |
0.263 |
|
| 2019 |
Pagani IS, Dang P, Saunders VA, Grose R, Shanmuganathan N, Kok CH, Carne L, Rwodzi Z, Watts S, McLean J, Braley J, Altamura H, Yeung DT, Branford S, Yong ASM, ... ... Hughes TP, et al. Lineage of measurable residual disease in patients with chronic myeloid leukemia in treatment-free remission. Leukemia. PMID 31768016 DOI: 10.1038/s41375-019-0647-x |
0.263 |
|
| 2008 |
Rutherford JC, Chua G, Hughes T, Cardenas ME, Heitman J. A Mep2-dependent transcriptional profile links permease function to gene expression during pseudohyphal growth in Saccharomyces cerevisiae. Molecular Biology of the Cell. 19: 3028-39. PMID 18434596 DOI: 10.1091/Mbc.E08-01-0033 |
0.263 |
|
| 2010 |
Hiwase DK, Engler J, Saunders V, White DL, Hughes T. In Contrast to Imatinib, Dasatinib Intracellular Concentration In CML-CD34+ Progenitors Is Not Significantly Different Than That Observed In CD34- Mature Cells. Blood. 116: 1205-1205. DOI: 10.1182/Blood.V116.21.1205.1205 |
0.262 |
|
| 2018 |
Segorbe D, Wilkinson D, Mizeranschi A, Hughes T, Aaløkken R, Vachova L, Palkova Z, Gilfillan GD. An optimized FAIRE procedure for low cell numbers in yeast. Yeast (Chichester, England). PMID 29577419 DOI: 10.1002/Yea.3316 |
0.262 |
|
| 2017 |
Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ, et al. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia. The New England Journal of Medicine. 376: 917-927. PMID 28273028 DOI: 10.1056/Nejmoa1609324 |
0.261 |
|
| 2011 |
Engler JR, Zannettino AC, Bailey CG, Rasko JE, Hughes TP, White DL. OCT-1 function varies with cell lineage but is not influenced by BCR-ABL. Haematologica. 96: 213-20. PMID 20971815 DOI: 10.3324/haematol.2010.033290 |
0.261 |
|
| 2014 |
Hughes TP, Saglio G, Kantarjian HM, Guilhot F, Niederwieser D, Rosti G, Nakaseko C, De Souza CA, Kalaycio ME, Meier S, Fan X, Menssen HD, Larson RA, Hochhaus A. Early molecular response predicts outcomes in patients with chronic myeloid leukemia in chronic phase treated with frontline nilotinib or imatinib. Blood. 123: 1353-60. PMID 24335106 DOI: 10.1182/blood-2013-06-510396 |
0.261 |
|
| 2018 |
Hughes T, Sønderby IE, Polushina T, Hansson L, Holmgren A, Athanasiu L, Melbø-Jørgensen C, Hassani S, Hoeffding LK, Herms S, Bergen SE, Karlsson R, Song J, Rietschel M, Nöthen MM, et al. Elevated expression of a minor isoform of ANK3 is a risk factor for bipolar disorder. Translational Psychiatry. 8: 210. PMID 30297702 DOI: 10.1038/S41398-018-0175-X |
0.26 |
|
| 2023 |
Shanmuganathan N, Wadham C, Shahrin N, Feng J, Thomson D, Wang P, Saunders V, Kok CH, King RM, Kenyon RR, Lin M, Pagani IS, Ross DM, Yong ASM, Grigg AP, ... ... Hughes TP, et al. Impact of additional genetic abnormalities at diagnosis of chronic myeloid leukemia for first-line imatinib-treated patients receiving proactive treatment intervention. Haematologica. PMID 36951160 DOI: 10.3324/haematol.2022.282184 |
0.26 |
|
| 2019 |
Kok CH, Yeung DT, Lu L, Watkins DB, Leclercq TM, Dang P, Saunders VA, Reynolds J, White DL, Hughes TP. Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinib. Blood Advances. 3: 1610-1621. PMID 31126916 DOI: 10.1182/bloodadvances.2019000195 |
0.26 |
|
| 2016 |
Barøy T, Pedurupillay CR, Bliksrud YT, Rasmussen M, Holmgren A, Vigeland MD, Hughes T, Brink M, Richard, Nedregaard B, Strømme P, Frengen E, Misceo D. A novel mutation in FBXL4 in a Norwegian child with encephalomyopathic mitochondrial DNA depletion syndrome 13. European Journal of Medical Genetics. PMID 27182039 DOI: 10.1016/J.Ejmg.2016.05.005 |
0.259 |
|
| 2003 |
Bader GD, Heilbut A, Andrews B, Tyers M, Hughes T, Boone C. Functional genomics and proteomics: charting a multidimensional map of the yeast cell. Trends in Cell Biology. 13: 344-56. PMID 12837605 DOI: 10.1016/S0962-8924(03)00127-2 |
0.258 |
|
| 2019 |
Branford S, Kim DDH, Apperley JF, Eide CA, Mustjoki S, Ong ST, Nteliopoulos G, Ernst T, Chuah C, Gambacorti-Passerini C, Mauro MJ, Druker BJ, Kim DW, Mahon FX, Cortes J, ... ... Hughes TP, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. Leukemia. PMID 31209280 DOI: 10.1038/S41375-019-0512-Y |
0.258 |
|
| 2023 |
Kok CH, Saunders VA, Dang P, Shanmuganathan N, White D, Branford S, Yeung D, Hughes TP. Adverse outcomes for chronic myeloid leukemia patients with splenomegaly and low in vivo kinase inhibition on imatinib. Blood Cancer Journal. 13: 143. PMID 37696829 DOI: 10.1038/s41408-023-00917-4 |
0.257 |
|
| 1992 |
Cullis J, Jiang Y, Schwarer A, Hughes T, Barrett A, Goldman J. Donor leukocyte infusions for chronic myeloid leukemia in relapse after allogeneic bone marrow transplantation. Blood. 79: 1379-1381. DOI: 10.1182/Blood.V79.5.1379.1379 |
0.255 |
|
| 2017 |
Maršíková J, Wilkinson D, Hlaváček O, Gilfillan GD, Mizeranschi A, Hughes T, Begany M, Rešetárová S, Váchová L, Palková Z. Metabolic differentiation of surface and invasive cells of yeast colony biofilms revealed by gene expression profiling. Bmc Genomics. 18: 814. PMID 29061122 DOI: 10.1186/S12864-017-4214-4 |
0.255 |
|
| 2017 |
Collins KM, Kainov YA, Christodolou E, Ray D, Morris Q, Hughes T, Taylor IA, Makeyev EV, Ramos A. An RRM-ZnF RNA recognition module targets RBM10 to exonic sequences to promote exon exclusion. Nucleic Acids Research. PMID 28379442 DOI: 10.1093/Nar/Gkx225 |
0.255 |
|
| 2012 |
Jabbour E, Saglio G, Hughes TP, Kantarjian H. Suboptimal responses in chronic myeloid leukemia: implications and management strategies. Cancer. 118: 1181-91. PMID 22038681 DOI: 10.1002/cncr.26391 |
0.255 |
|
| 2010 |
Hiwase DK, Eadie L, Saunders V, Hughes T, White DL. Proton Pump Inhibitors Augment Nilotinib and Dasatinib Mediated Bcr-Abl Kinase Inhibition Blood. 116: 3991-3991. DOI: 10.1182/Blood.V116.21.3991.3991 |
0.254 |
|
| 2018 |
Shanmuganathan N, Hughes TP. Molecular monitoring in CML: How deep? How often? How should it influence therapy? Blood. PMID 30429156 DOI: 10.1182/blood-2018-05-848630 |
0.253 |
|
| 2020 |
Thomson DW, Shahrin NH, Wang PPS, Wadham C, Shanmuganathan N, Scott HS, Dinger ME, Hughes TP, Schreiber AW, Branford S. Aberrant RAG-mediated recombination contributes to multiple structural rearrangements in lymphoid blast crisis of chronic myeloid leukemia. Leukemia. PMID 32076119 DOI: 10.1038/s41375-020-0751-y |
0.253 |
|
| 2020 |
Hughes T, Hansson L, Akkouh I, Hajdarevic R, Bringsli JS, Torsvik A, Inderhaug E, Steen VM, Djurovic S. Runaway multi-allelic copy number variation at the α-defensin locus in African and Asian populations. Scientific Reports. 10: 9101. PMID 32499510 DOI: 10.1038/S41598-020-65675-W |
0.253 |
|
| 2018 |
Shanmuganathan N, Hughes TP. Molecular monitoring in CML: how deep? How often? How should it influence therapy? Hematology. American Society of Hematology. Education Program. 2018: 168-176. PMID 30504306 DOI: 10.1182/asheducation-2018.1.168 |
0.252 |
|
| 2005 |
Savchenko A, Krogan N, Cort JR, Evdokimova E, Lew JM, Yee AA, Sánchez-Pulido L, Andrade MA, Bochkarev A, Watson JD, Kennedy MA, Greenblatt J, Hughes T, Arrowsmith CH, Rommens JM, et al. The Shwachman-Bodian-Diamond syndrome protein family is involved in RNA metabolism. The Journal of Biological Chemistry. 280: 19213-20. PMID 15701634 DOI: 10.1074/Jbc.M414421200 |
0.252 |
|
| 2016 |
Tesli M, Wirgenes KV, Hughes T, Bettella F, Athanasiu L, Hoseth ES, Nerhus M, Lagerberg TV, Steen NE, Agartz I, Melle I, Dieset I, Djurovic S, Andreassen OA. VRK2 gene expression in schizophrenia, bipolar disorder and healthy controls. The British Journal of Psychiatry : the Journal of Mental Science. PMID 26941264 DOI: 10.1192/Bjp.Bp.115.161950 |
0.252 |
|
| 2003 |
Nedea E, He X, Kim M, Pootoolal J, Zhong G, Canadien V, Hughes T, Buratowski S, Moore CL, Greenblatt J. Organization and function of APT, a subcomplex of the yeast cleavage and polyadenylation factor involved in the formation of mRNA and small nucleolar RNA 3'-ends. The Journal of Biological Chemistry. 278: 33000-10. PMID 12819204 DOI: 10.1074/Jbc.M304454200 |
0.252 |
|
| 2014 |
Hughes TP, Lipton JH, Spector N, Cervantes F, Pasquini R, Clementino NC, Dorlhiac Llacer PE, Schwarer AP, Mahon FX, Rea D, Branford S, Purkayastha D, Collins L, Szczudlo T, Leber B. Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. Blood. 124: 729-36. PMID 24948656 DOI: 10.1182/blood-2013-12-544015 |
0.252 |
|
| 2016 |
Sundaram AY, Hughes T, Biondi S, Bolduc N, Bowman SK, Camilli A, Chew YC, Couture C, Farmer A, Jerome JP, Lazinski DW, McUsic A, Peng X, Shazand K, Xu F, et al. A comparative study of ChIP-seq sequencing library preparation methods. Bmc Genomics. 17: 816. PMID 27769162 DOI: 10.1186/S12864-016-3135-Y |
0.251 |
|
| 2023 |
Shanmuganathan N, Hughes TP. Accelerated-phase CML: de novo and transformed. Hematology. American Society of Hematology. Education Program. 2023: 459-468. PMID 38066863 DOI: 10.1182/hematology.2023000446 |
0.251 |
|
| 2021 |
Rea D, Mauro MJ, Boquimpani C, Minami Y, Lomaia E, Voloshin S, Turkina AG, Kim DW, Apperley JF, Abdo A, Fogliatto LM, Kim DDH, le Coutre P, Saussele S, Annunziata M, ... Hughes TP, et al. A Phase 3, Open-Label, Randomized Study of Asciminib, a STAMP Inhibitor, vs Bosutinib in CML After ≥2 Prior TKIs. Blood. PMID 34407542 DOI: 10.1182/blood.2020009984 |
0.251 |
|
| 2012 |
Xu M, Soloveychik M, Ranger M, Schertzberg M, Shah Z, Raisner R, Venkatasubrahmanyan S, Tsui K, Gebbia M, Hughes T, van Bakel H, Nislow C, Madhani HD, Meneghini MD. Timing of transcriptional quiescence during gametogenesis is controlled by global histone H3K4 demethylation. Developmental Cell. 23: 1059-71. PMID 23123093 DOI: 10.1016/J.Devcel.2012.10.005 |
0.25 |
|
| 2019 |
Chhetri R, Wee LYA, Sinha R, Kutyna MM, Pham A, Stathopoulos H, Nath L, Nath SV, Wickham N, Hughes T, Singhal D, Roxby DJ, Hiwase DK. Red cell autoimmunization and alloimmunization in myelodysplastic syndromes: prevalence, characteristic and significance. Haematologica. PMID 30819906 DOI: 10.3324/Haematol.2018.215087 |
0.25 |
|
| 2010 |
Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, et al. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS). Blood. 116: 3758-65. PMID 20679528 DOI: 10.1182/Blood-2010-03-273979 |
0.249 |
|
| 2023 |
Mauro MJ, Hughes TP, Kim DW, Rea D, Cortes JE, Hochhaus A, Sasaki K, Breccia M, Talpaz M, Ottmann O, Minami H, Goh YT, DeAngelo DJ, Heinrich MC, Gómez-García de Soria V, et al. Asciminib monotherapy in patients with CML-CP without BCR::ABL1 T315I mutations treated with at least two prior TKIs: 4-year phase 1 safety and efficacy results. Leukemia. PMID 36949155 DOI: 10.1038/s41375-023-01860-w |
0.249 |
|
| 2018 |
Cortes JE, Kim DW, Pinilla-Ibarz J, le Coutre PD, Paquette R, Chuah C, Nicolini FE, Apperley JF, Khoury HJ, Talpaz M, DeAngelo DJ, Abruzzese E, Rea D, Baccarani M, Müller MC, ... ... Hughes TP, et al. Ponatinib efficacy and safety in Philadelphia chromosome-positive leukemia: final 5-year results of the phase 2 PACE trial. Blood. PMID 29567798 DOI: 10.1182/Blood-2016-09-739086 |
0.249 |
|
| 2015 |
Yeung DT, Tang C, Vidovic L, White DL, Branford S, Hughes TP, Yong AS. KIR2DL5B genotype predicts outcomes in CML patients treated with response directed sequential imatinib / nilotinib strategy. Blood. PMID 26500342 DOI: 10.1182/blood-2015-07-655589 |
0.248 |
|
| 2004 |
Szer J, Durrant S, Schwarer AP, Bradstock KF, Gibson J, Arthur C, To LB, Hughes T, Raunow H. Oral versus intravenous ganciclovir for the prophylaxis of cytomegalovirus disease after allogeneic bone marrow transplantation. Internal Medicine Journal. 34: 98-101. PMID 15030456 DOI: 10.1111/J.1444-0903.2004.00550.X |
0.247 |
|
| 2018 |
Akkouh IA, Ueland T, Andreassen OA, Brattbakk HR, Steen VM, Hughes T, Djurovic S. Expression of TCN1 in Blood is Negatively Associated with Verbal Declarative Memory Performance. Scientific Reports. 8: 12654. PMID 30139959 DOI: 10.1038/S41598-018-30898-5 |
0.246 |
|
| 2022 |
Poudel G, Tolland MG, Hughes TP, Pagani IS. Mechanisms of Resistance and Implications for Treatment Strategies in Chronic Myeloid Leukaemia. Cancers. 14. PMID 35884363 DOI: 10.3390/cancers14143300 |
0.246 |
|
| 2011 |
White DL, Hughes TP. Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Current Hematologic Malignancy Reports. 6: 88-95. PMID 21448598 DOI: 10.1007/s11899-011-0087-9 |
0.246 |
|
| 2013 |
Hochhaus A, Saglio G, Larson RA, Kim DW, Etienne G, Rosti G, De Souza C, Kurokawa M, Kalaycio ME, Hoenekopp A, Fan X, Shou Y, Kantarjian HM, Hughes TP. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase. Blood. 121: 3703-8. PMID 23502220 DOI: 10.1182/blood-2012-04-423418 |
0.246 |
|
| 2018 |
Witoelar A, Rongve A, Almdahl IS, Ulstein ID, Engvig A, White LR, Selbæk G, Stordal E, Andersen F, Brækhus A, Saltvedt I, Engedal K, Hughes T, Bergh S, Bråthen G, et al. Meta-analysis of Alzheimer's disease on 9,751 samples from Norway and IGAP study identifies four risk loci. Scientific Reports. 8: 18088. PMID 30591712 DOI: 10.1038/S41598-018-36429-6 |
0.246 |
|
| 2010 |
Gould CM, Diella F, Via A, Puntervoll P, Gemünd C, Chabanis-Davidson S, Michael S, Sayadi A, Bryne JC, Chica C, Seiler M, Davey NE, Haslam N, Weatheritt RJ, Budd A, ... Hughes T, et al. ELM: the status of the 2010 eukaryotic linear motif resource. Nucleic Acids Research. 38: D167-80. PMID 19920119 DOI: 10.1093/Nar/Gkp1016 |
0.245 |
|
| 2022 |
Hughes TP, Cortes J, Takahashi N, Larson R, Issa GC, Bombaci F, Ramscar N, Kapoor S, Ifrah S, Hochhaus A. CML-423 Trial in Progress: A Phase III Study of Asciminib vs an Investigator-Selected Tyrosine Kinase Inhibitor (TKI) in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP). Clinical Lymphoma, Myeloma & Leukemia. S297-S298. PMID 36163929 DOI: 10.1016/S2152-2650(22)01383-0 |
0.245 |
|
| 2012 |
White DL, Radich J, Soverini S, Saunders VA, Frede AK, Dang P, Cilloni D, Lin P, Mongay L, Woodman R, Manley P, Slader C, Kim DW, Pane F, Martinelli G, ... ... Hughes TP, et al. Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinib. Haematologica. 97: 907-14. PMID 22207690 DOI: 10.3324/haematol.2011.056457 |
0.244 |
|
| 2015 |
Hughes T, Hansson L, Sønderby IE, Athanasiu L, Zuber V, Tesli M, Song J, Hultman CM, Bergen SE, Landén M, Melle I, Andreassen OA, Djurovic S. A Loss-of-Function Variant in a Minor Isoform of ANK3 Protects Against Bipolar Disorder and Schizophrenia. Biological Psychiatry. PMID 26682468 DOI: 10.1016/J.Biopsych.2015.09.021 |
0.244 |
|
| 2004 |
Hughes T, Andrews B, Boone C. Old Drugs, New Tricks: Using Genetically Sensitized Yeast to Reveal Drug Targets Cell. 116: 5-7. PMID 14718160 DOI: 10.1016/S0092-8674(03)01070-5 |
0.244 |
|
| 2014 |
Wirgenes KV, Tesli M, Inderhaug E, Athanasiu L, Agartz I, Melle I, Hughes T, Andreassen OA, Djurovic S. ANK3 gene expression in bipolar disorder and schizophrenia. The British Journal of Psychiatry : the Journal of Mental Science. 205: 244-5. PMID 24809399 DOI: 10.1192/Bjp.Bp.114.145433 |
0.242 |
|
| 2021 |
Krishnan V, Kim DDH, Hughes TP, Branford S, Ong ST. Integrating genetic and epigenetic factors in chronic myeloid leukemia risk assessment: toward gene expression-based biomarkers. Haematologica. PMID 34615339 DOI: 10.3324/haematol.2021.279317 |
0.242 |
|
| 2014 |
Ross DM, Hughes TP. How I determine if and when to recommend stopping tyrosine kinase inhibitor treatment for chronic myeloid leukaemia. British Journal of Haematology. 166: 3-11. PMID 24754670 DOI: 10.1111/bjh.12892 |
0.242 |
|
| 2018 |
Branford S, Wang P, Yeung DT, Thomson D, Purins A, Wadham C, Shahrin NH, Marum JE, Nataren N, Parker WT, Geoghegan J, Feng J, Shanmuganathan N, Mueller MC, Dietz C, ... ... Hughes TP, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high risk disease. Blood. PMID 29967129 DOI: 10.1182/Blood-2018-02-832253 |
0.241 |
|
| 2012 |
Lyle R, Hughes T, Undlien D, Jakobsen K. The Norwegian Sequencing Centre (NSC) Embnet.Journal. 17: 22. DOI: 10.14806/Ej.17.B.258 |
0.241 |
|
| 2018 |
Shanmuganathan N, Branford S, Yong A, Hiwase D, Yeung D, Ross D, Hughes T. Predictors of Success in Treatment-Free Remission: A Single Centre Experience Clinical Lymphoma, Myeloma & Leukemia. 18. DOI: 10.1016/J.Clml.2018.07.095 |
0.24 |
|
| 2015 |
le Coutre PD, Hughes TP, Mahon FX, Kim DW, Steegmann JL, Shah NP, Gooden K, Wallis N, Cortes JE. Low incidence of peripheral arterial disease in patients receiving dasatinib in clinical trials. Leukemia. PMID 26686247 DOI: 10.1038/Leu.2015.352 |
0.24 |
|
| 2014 |
Baccarani M, Druker BJ, Branford S, Kim DW, Pane F, Mongay L, Mone M, Ortmann CE, Kantarjian HM, Radich JP, Hughes TP, Cortes JE, Guilhot F. Long-term response to imatinib is not affected by the initial dose in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: final update from the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) study. International Journal of Hematology. 99: 616-24. PMID 24658916 DOI: 10.1007/S12185-014-1566-2 |
0.239 |
|
| 2011 |
Esposito N, Colavita I, Quintarelli C, Sica AR, Peluso AL, Luciano L, Picardi M, Del Vecchio L, Buonomo T, Hughes TP, White D, Radich JP, Russo D, Branford S, Saglio G, et al. SHP-1 expression accounts for resistance to imatinib treatment in Philadelphia chromosome-positive cells derived from patients with chronic myeloid leukemia. Blood. 118: 3634-44. PMID 21821701 DOI: 10.1182/blood-2011-03-341073 |
0.239 |
|
| 2012 |
Parker WT, Ho M, Scott HS, Hughes TP, Branford S. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood. 119: 2234-8. PMID 22210874 DOI: 10.1182/blood-2011-08-375535 |
0.239 |
|
| 1990 |
Hughes T, Janssen JWG, Morgan G, Martiat P, Saglio G, Pignon JM, Pignatti FP, Mills K, Keating A, Gluckman E, Bartram CR, Goldman JM. False-positive results with PCR to detect leukaemia-specific transcript. The Lancet. 335: 1037-1038. PMID 1970088 DOI: 10.1016/0140-6736(90)91102-G |
0.238 |
|
| 2013 |
Branford S, Yeung DT, Ross DM, Prime JA, Field CR, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Sullivan B, Briggs NE, Hertzberg M, Seymour JF, Reynolds J, ... Hughes TP, et al. Early molecular response and female sex strongly predict stable undetectable BCR-ABL1, the criteria for imatinib discontinuation in patients with CML. Blood. 121: 3818-24. PMID 23515925 DOI: 10.1182/blood-2012-10-462291 |
0.238 |
|
| 2009 |
Müller MC, Cortes JE, Kim DW, Druker BJ, Erben P, Pasquini R, Branford S, Hughes TP, Radich JP, Ploughman L, Mukhopadhyay J, Hochhaus A. Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations. Blood. 114: 4944-53. PMID 19779040 DOI: 10.1182/Blood-2009-04-214221 |
0.238 |
|
| 2022 |
Réa D, Hochhaus A, Mauro MJ, Minami Y, Lomaia E, Voloshin S, Turkina A, Kim DW, Apperley JF, Cortes JE, Abdo A, Fogliatto LM, Kim DDH, Coutre PL, Saussele S, ... ... Hughes TP, et al. CML-395 Efficacy and Safety Results From ASCEMBL, a Phase III Study of Asciminib vs. Bosutinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) After ≥2 Prior Tyrosine Kinase Inhibitors (TKIs): Week 96 Update. Clinical Lymphoma, Myeloma & Leukemia. S295-S296. PMID 36163925 DOI: 10.1016/S2152-2650(22)01379-9 |
0.237 |
|
| 2012 |
White DL, Hughes TP. Classification of patients with chronic myeloid leukemia on basis of BCR-ABL transcript level at 3 months fails to identify patients with low organic cation transporter-1 activity destined to have poor imatinib response. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 1144-5; author reply. PMID 22393079 DOI: 10.1200/JCO.2011.41.1090 |
0.237 |
|
| 2016 |
Hughes TP, Ross DM. Moving treatment-free remission into mainstream clinical practice in CML. Blood. PMID 27013442 DOI: 10.1182/blood-2016-01-694265 |
0.236 |
|
| 2022 |
Cortes JE, Hochhaus A, Takahashi N, Larson RA, Issa GC, Bombaci F, Ramscar N, Ifrah S, Hughes TP. Asciminib monotherapy for newly diagnosed chronic myeloid leukemia in chronic phase: the ASC4FIRST phase III trial. Future Oncology (London, England). PMID 36524980 DOI: 10.2217/fon-2022-0923 |
0.236 |
|
| 2014 |
Jabbour EJ, Hughes TP, Cortés JE, Kantarjian HM, Hochhaus A. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia. Leukemia & Lymphoma. 55: 1451-62. PMID 24050507 DOI: 10.3109/10428194.2013.845883 |
0.235 |
|
| 2013 |
Stein AM, Martinelli G, Hughes TP, Müller MC, Beppu L, Gottardi E, Branford S, Soverini S, Woodman RC, Hochhaus A, Kim DW, Saglio G, Radich JP. Rapid initial decline in BCR-ABL1 is associated with superior responses to second-line nilotinib in patients with chronic-phase chronic myeloid leukemia. Bmc Cancer. 13: 173. PMID 23547655 DOI: 10.1186/1471-2407-13-173 |
0.235 |
|
| 2022 |
Hughes TP, Shanmuganathan N. Management of TKI-resistant chronic phase CML. Hematology. American Society of Hematology. Education Program. 2022: 129-137. PMID 36485117 DOI: 10.1182/hematology.2022000328 |
0.235 |
|
| 2015 |
Rasmussen HB, Bjerre D, Linnet K, Jürgens G, Dalhoff K, Stefansson H, Hankemeier T, Kaddurah-Daouk R, Taboureau O, Brunak S, Houmann T, Jeppesen P, Pagsberg AK, Plessen K, Dyrborg J, ... ... Hughes T, et al. Individualization of treatments with drugs metabolized by CES1: combining genetics and metabolomics. Pharmacogenomics. 16: 649-65. PMID 25896426 DOI: 10.2217/Pgs.15.7 |
0.235 |
|
| 1990 |
Hughes T, Martiat P, Morgan G, Sawyers C, Witte ON, Goldman ON. Significance of residual leukaemia transcripts after bone marrow transplant for CML. Lancet (London, England). 335: 50. PMID 1967352 DOI: 10.1016/0140-6736(90)90175-5 |
0.234 |
|
| 2018 |
Hughes TP, Laneuville P, Rousselot P, Snyder DS, Rea D, Shah NP, Paar D, Abruzzese E, Hochhaus A, Lipton JH, Cortes JE. Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia. Haematologica. PMID 30093398 DOI: 10.3324/Haematol.2018.188987 |
0.233 |
|
| 2009 |
Ross DM, Branford S, Melo JV, Hughes TP. Reply to 'What do we mean by sensitivity when we talk about detecting minimal residual disease?' by Steinbach and Debatin Leukemia. 23: 819-820. PMID 19020541 DOI: 10.1038/Leu.2008.330 |
0.233 |
|
| 2004 |
Mullighan C, Heatley S, Doherty K, Szabo F, Grigg A, Hughes T, Schwarer A, Szer J, Tait B, To B, Bardy P. Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantation. Transplantation. 77: 587-96. PMID 15084940 DOI: 10.1097/01.Tp.0000111769.45088.A2 |
0.231 |
|
| 2009 |
White DL, Hughes TP. Predicting the response of CML patients to tyrosine kinase inhibitor therapy. Current Hematologic Malignancy Reports. 4: 59-65. PMID 20425416 DOI: 10.1007/s11899-009-0009-2 |
0.231 |
|
| 2022 |
Yeung DT, Shanmuganathan N, Hughes TP. Asciminib: new therapeutic option in chronic phase CML with treatment failure. Blood. PMID 35468180 DOI: 10.1182/blood.2021014689 |
0.231 |
|
| 2013 |
Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, Cervantes F, Clark RE, Cortes JE, Guilhot F, Hjorth-Hansen H, Hughes TP, Kantarjian HM, Kim DW, Larson RA, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 122: 872-84. PMID 23803709 DOI: 10.1182/blood-2013-05-501569 |
0.231 |
|
| 2005 |
Hui CH, Hughes TP. Strategies for the treatment of imatinib-resistant chronic myeloid leukemia. Clinical Advances in Hematology & Oncology : H&O. 1: 538-45, 559. PMID 16258446 |
0.23 |
|
| 2008 |
Hughes TP, Branford S, White DL, Reynolds J, Koelmeyer R, Seymour JF, Taylor K, Arthur C, Schwarer A, Morton J, Cooney J, Leahy MF, Rowlings P, Catalano J, Hertzberg M, et al. Impact of early dose intensity on cytogenetic and molecular responses in chronic- phase CML patients receiving 600 mg/day of imatinib as initial therapy. Blood. 112: 3965-73. PMID 18768781 DOI: 10.1182/blood-2008-06-161737 |
0.23 |
|
| 2004 |
Melo JV, Hughes TP, Apperley JF. Chronic myeloid leukemia. Hematology. American Society of Hematology. Education Program. 132-52. PMID 14633780 DOI: 10.1182/asheducation-2003.1.132 |
0.23 |
|
| 2011 |
Parker WT, Lawrence RM, Ho M, Irwin DL, Scott HS, Hughes TP, Branford S. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 4250-9. PMID 21990409 DOI: 10.1200/JCO.2011.35.0934 |
0.229 |
|
| 2003 |
Roth C, Hughes T. From microarrays to genome duplications. Genome Biology. 4: 332-332. PMID 12914655 DOI: 10.1186/Gb-2003-4-8-332 |
0.229 |
|
| 2014 |
Hughes TP, Hochhaus A, Kantarjian HM, Cervantes F, Guilhot F, Niederwieser D, le Coutre PD, Rosti G, Ossenkoppele G, Lobo C, Shibayama H, Fan X, Menssen HD, Kemp C, Larson RA, et al. Safety and efficacy of switching to nilotinib 400 mg twice daily for patients with chronic myeloid leukemia in chronic phase with suboptimal response or failure on front-line imatinib or nilotinib 300 mg twice daily. Haematologica. 99: 1204-11. PMID 24532039 DOI: 10.3324/haematol.2013.091272 |
0.229 |
|
| 2016 |
Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, Gambacorti-Passerini C, Saglio G, Cortes J, Daley GQ. Chronic myeloid leukemia: reminiscences and dreams. Haematologica. 101: 541-558. PMID 27132280 DOI: 10.3324/Haematol.2015.139337 |
0.228 |
|
| 2014 |
Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, ... ... Hughes TP, et al. Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 124: 511-8. PMID 24859364 DOI: 10.1182/Blood-2014-03-566323 |
0.228 |
|
| 2005 |
Michor F, Hughes TP, Iwasa Y, Branford S, Shah NP, Sawyers CL, Nowak MA. Dynamics of chronic myeloid leukaemia. Nature. 435: 1267-70. PMID 15988530 DOI: 10.1038/Nature03669 |
0.228 |
|
| 2008 |
Ross DM, Watkins DB, Hughes TP, Branford S. Reverse transcription with random pentadecamer primers improves the detection limit of a quantitative PCR assay for BCR-ABL transcripts in chronic myeloid leukemia: Implications for defining sensitivity in minimal residual disease Clinical Chemistry. 54: 1568-1571. PMID 18641042 DOI: 10.1373/clinchem.2008.105916 |
0.228 |
|
| 2010 |
White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, Saunders VA, Manley PW, Hughes TP. Functional activity of the OCT-1 protein is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 2761-7. PMID 20421539 DOI: 10.1200/JCO.2009.26.5819 |
0.227 |
|
| 2015 |
Deininger MW, Hodgson JG, Shah NP, Cortes JE, Kim DW, Nicolini FE, Talpaz M, Baccarani M, Müller MC, Li J, Parker WT, Lustgarten S, Clackson T, Haluska FG, Guilhot F, ... ... Hughes TP, et al. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients. Blood. PMID 26603839 DOI: 10.1182/Blood-2015-08-660977 |
0.227 |
|
| 2002 |
Branford S, Rudzki Z, Walsh S, Grigg A, Arthur C, Taylor K, Herrmann R, Lynch KP, Hughes TP. High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood. 99: 3472-5. PMID 11964322 DOI: 10.1182/blood.v99.9.3472 |
0.227 |
|
| 2017 |
Sadras T, Heatley SL, Kok CH, McClure BJ, Yeung D, Hughes TP, Sutton R, Ziegler DS, White DL. A novel somatic JAK2 kinase-domain mutation in pediatric acute lymphoblastic leukemia with rapid on-treatment development of LOH. Cancer Genetics. 216: 86-90. PMID 29025600 DOI: 10.1016/j.cancergen.2017.07.008 |
0.226 |
|
| 2013 |
Angelini S, Soverini S, Ravegnini G, Barnett M, Turrini E, Thornquist M, Pane F, Hughes TP, White DL, Radich J, Kim DW, Saglio G, Cilloni D, Iacobucci I, Perini G, et al. Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy. Haematologica. 98: 193-200. PMID 22875622 DOI: 10.3324/haematol.2012.066480 |
0.226 |
|
| 2007 |
Shah NP, Skaggs BJ, Branford S, Hughes TP, Nicoll JM, Paquette RL, Sawyers CL. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency Journal of Clinical Investigation. 117: 2562-2569. PMID 17710227 DOI: 10.1172/Jci30890 |
0.226 |
|
| 2021 |
Heatley SL, Asari K, Schutz CE, Leclercq TM, McClure BJ, Eadie LN, Hughes TP, Yeung DT, White DL. modeling of TKI resistance in the high-risk B-cell acute lymphoblastic leukemia fusion gene - implications for targeted therapy. Leukemia & Lymphoma. 1-13. PMID 33390067 DOI: 10.1080/10428194.2020.1861275 |
0.225 |
|
| 2011 |
Tang M, Gonen M, Quintas-Cardama A, Cortes J, Kantarjian H, Field C, Hughes TP, Branford S, Michor F. Dynamics of chronic myeloid leukemia response to long-term targeted therapy reveal treatment effects on leukemic stem cells. Blood. 118: 1622-31. PMID 21653938 DOI: 10.1182/Blood-2011-02-339267 |
0.225 |
|
| 2022 |
Shanmuganathan N, Hughes TP. Asciminib for chronic myeloid leukaemia: Next questions. British Journal of Haematology. PMID 35729850 DOI: 10.1111/bjh.18323 |
0.225 |
|
| 2018 |
Mahon FX, Boquimpani C, Kim DW, Benyamini N, Clementino NCD, Shuvaev V, Ailawadhi S, Lipton JH, Turkina AG, De Paz R, Moiraghi B, Nicolini FE, Dengler J, Sacha T, Takahashi N, ... ... Hughes TP, et al. Treatment-Free Remission After Second-Line Nilotinib Treatment in Patients With Chronic Myeloid Leukemia in Chronic Phase: Results From a Single-Group, Phase 2, Open-Label Study. Annals of Internal Medicine. PMID 29459949 DOI: 10.7326/M17-1094 |
0.225 |
|
| 2022 |
Hughes TP, Cortes JE, Réa D, Mauro MJ, Hochhaus A, Kim DW, Sasaki K, Lang F, Heinrich MC, Breccia M, Deininger M, Goh YT, Janssen JJWM, Talpaz M, Coutre PL, et al. CML-466 Asciminib Provides Durable Molecular Responses in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With the T315I Mutation: Updated Efficacy and Safety Data From a Phase I Trial. Clinical Lymphoma, Myeloma & Leukemia. S300. PMID 36163936 DOI: 10.1016/S2152-2650(22)01388-X |
0.224 |
|
| 2015 |
Farooqui MZ, Valdez J, Martyr S, Aue G, Saba N, Niemann CU, Herman SE, Tian X, Marti G, Soto S, Hughes TE, Jones J, Lipsky A, Pittaluga S, Stetler-Stevenson M, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. The Lancet. Oncology. 16: 169-76. PMID 25555420 DOI: 10.1016/S1470-2045(14)71182-9 |
0.224 |
|
| 2012 |
Hamfjord J, Stangeland AM, Hughes T, Skrede ML, Tveit KM, Ikdahl T, Kure EH. Differential expression of miRNAs in colorectal cancer: Comparison of paired tumor tissue and adjacent normal mucosa using high-throughput sequencing Plos One. 7. PMID 22529906 DOI: 10.1371/Journal.Pone.0034150 |
0.223 |
|
| 2012 |
Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC. Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 30: 4323-9. PMID 23109697 DOI: 10.1200/JCO.2011.40.5217 |
0.221 |
|
| 2021 |
Page EC, Heatley SL, Eadie LN, McClure BJ, de Bock CE, Omari S, Yeung DT, Hughes TP, Thomas PQ, White DL. HMGN1 plays a significant role in CRLF2 driven Down Syndrome leukemia and provides a potential therapeutic target in this high-risk cohort. Oncogene. PMID 34857887 DOI: 10.1038/s41388-021-02126-4 |
0.221 |
|
| 2015 |
Yeung DT, Osborn MP, White DL, Branford S, Braley J, Herschtal A, Kornhauser M, Issa S, Hiwase DK, Hertzberg M, Schwarer AP, Filshie R, Arthur CK, Kwan YL, Trotman J, ... ... Hughes TP, et al. TIDEL-II: first-line use of imatinib in CML with early switch to nilotinib for failure to achieve time-dependent molecular targets. Blood. 125: 915-23. PMID 25519749 DOI: 10.1182/blood-2014-07-590315 |
0.221 |
|
| 2018 |
Pagani IS, Dang P, Kommers IO, Goyne JM, Nicola M, Saunders VA, Braley J, White DL, Yeung DT, Branford S, Hughes TP, Ross DM. BCR-ABL1 genomic DNA PCR response kinetics during first-line imatinib treatment of chronic myeloid leukemia. Haematologica. PMID 29976745 DOI: 10.3324/haematol.2018.189787 |
0.22 |
|
| 2013 |
Hercus TR, Dhagat U, Kan WL, Broughton SE, Nero TL, Perugini M, Sandow JJ, D'Andrea RJ, Ekert PG, Hughes T, Parker MW, Lopez AF. Signalling by the βc family of cytokines. Cytokine & Growth Factor Reviews. 24: 189-201. PMID 23535386 DOI: 10.1016/J.Cytogfr.2013.03.002 |
0.219 |
|
| 2017 |
Hercus TR, Kan WLT, Broughton SE, Tvorogov D, Ramshaw HS, Sandow JJ, Nero TL, Dhagat U, Thompson EJ, Shing KSCT, McKenzie DR, Wilson NJ, Owczarek CM, Vairo G, Nash AD, ... ... Hughes T, et al. Role of the β Common (βc) Family of Cytokines in Health and Disease. Cold Spring Harbor Perspectives in Biology. PMID 28716883 DOI: 10.1101/Cshperspect.A028514 |
0.218 |
|
| 2019 |
Szabo A, Akkouh IA, Hansson L, Inderhaug E, Hughes T, Ueland T, Steen NE, Andreassen OA, Djurovic S. Abstract #4389 Reduced IL-1beta-induced chemokine response in human iPSC-astrocytes in schizophrenia revealed by RNA-sequencing Brain Behavior and Immunity. 81: 50-51. DOI: 10.1016/J.Bbi.2019.08.167 |
0.217 |
|
| 2022 |
Shirazi PT, Eadie LN, Heatley SL, Page EC, François M, Hughes TP, Yeung D, White DL. Exploring the oncogenic and therapeutic target potential of the MYB-TYK2 fusion gene in B-cell acute lymphoblastic leukemia. Cancer Gene Therapy. PMID 35022522 DOI: 10.1038/s41417-021-00421-6 |
0.217 |
|
| 2011 |
Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP. Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. The Lancet. Oncology. 12: 841-51. PMID 21856226 DOI: 10.1016/S1470-2045(11)70201-7 |
0.216 |
|
| 2014 |
Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S. Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Blood. 124: 153-5. PMID 24993880 DOI: 10.1182/blood-2014-05-573485 |
0.214 |
|
| 2017 |
Hughes TP, Munhoz E, Aurelio Salvino M, Ong TC, Elhaddad A, Shortt J, Quach H, Pavlovsky C, Louw VJ, Shih LY, Turkina AG, Meillon L, Jin Y, Acharya S, Dalal D, et al. Nilotinib dose-optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd. British Journal of Haematology. PMID 28699641 DOI: 10.1111/bjh.14829 |
0.214 |
|
| 1978 |
Nalin D, Rhead J, Rennels M, O'Donnell S, Levine M, Bergquist E, Hughes T, Hornick R. Cannabis, Hypochlorhydria, And Cholera The Lancet. 312: 859-862. PMID 81411 DOI: 10.1016/S0140-6736(78)91569-6 |
0.212 |
|
| 2015 |
Lickliter JD, Taylor K, Szer J, Grigg A, Arthur C, Hughes TP, Durrant S, Filshie R, Irving I, Seldon M, Ellacott J, Boyd AW, D'Rozario J, Rooney K, Lynch K, et al. An imatinib-only window followed by imatinib and chemotherapy for Philadelphia chromosome-positive acute leukemia: long-term results of the CMLALL1 trial. Leukemia & Lymphoma. 56: 630-8. PMID 24844361 DOI: 10.3109/10428194.2014.925547 |
0.212 |
|
| 2014 |
Roberts KG, Li Y, Payne-Turner D, Harvey RC, Yang YL, Pei D, McCastlain K, Ding L, Lu C, Song G, Ma J, Becksfort J, Rusch M, Chen SC, Easton J, ... ... Hughes TP, et al. Targetable kinase-activating lesions in Ph-like acute lymphoblastic leukemia. The New England Journal of Medicine. 371: 1005-15. PMID 25207766 DOI: 10.1056/Nejmoa1403088 |
0.21 |
|
| 2011 |
Branford S, Hughes TP. Mutational analysis in chronic myeloid leukemia: when and what to do? Current Opinion in Hematology. 18: 111-6. PMID 21245758 DOI: 10.1097/MOH.0b013e32834399ef |
0.209 |
|
| 2020 |
Ross DM, Hughes TP. Treatment-free remission in patients with chronic myeloid leukaemia. Nature Reviews. Clinical Oncology. PMID 32377005 DOI: 10.1038/s41571-020-0367-1 |
0.207 |
|
| 2010 |
Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. The New England Journal of Medicine. 362: 2251-9. PMID 20525993 DOI: 10.1056/NEJMoa0912614 |
0.206 |
|
| 2006 |
Hui CH, Hughes TP. Autologous stem cell collection and autograft for patients with chronic myeloid leukemia in the era of ABL kinase inhibitors: Back to the bench Leukemia and Lymphoma. 47: 1721-1723. PMID 17064975 DOI: 10.1080/10428190600727871 |
0.205 |
|
| 2019 |
Tavakoli Shirazi P, Eadie LN, Heatley SL, Hughes TP, Yeung DT, White DL. The effect of co-occurring lesions on leukaemogenesis and drug response in T-ALL and ETP-ALL. British Journal of Cancer. PMID 31792348 DOI: 10.1038/s41416-019-0647-7 |
0.205 |
|
| 2023 |
Irani YD, Hughes A, Kok CH, Clarson J, Yeung DT, Ross DM, Branford S, Hughes TP, Yong ASM. Immune modulation in chronic myeloid leukaemia patients treated with nilotinib and interferon-alpha. British Journal of Haematology. PMID 37482935 DOI: 10.1111/bjh.18984 |
0.205 |
|
| 2022 |
Réa D, Hughes TP. Development of Asciminib, a Novel Allosteric Inhibitor of BCR-ABL1. Critical Reviews in Oncology/Hematology. 103580. PMID 35021069 DOI: 10.1016/j.critrevonc.2022.103580 |
0.203 |
|
| 2012 |
Yeung DT, Hughes TP. Therapeutic targeting of BCR-ABL: prognostic markers of response and resistance mechanism in chronic myeloid leukaemia. Critical Reviews in Oncogenesis. 17: 17-30. PMID 22471662 |
0.203 |
|
| 2019 |
Shanmuganathan N, Hughes TP. Early Management of CML. Current Hematologic Malignancy Reports. PMID 31701368 DOI: 10.1007/s11899-019-00550-8 |
0.202 |
|
| 2007 |
Hughes T, Rusten TE. Origin and Evolution of Self-Consumption: Autophagy Advances in Experimental Medicine and Biology. 607: 111-118. PMID 17977463 DOI: 10.1007/978-0-387-74021-8_9 |
0.202 |
|
| 2008 |
Fitter S, Dewar AL, Kostakis P, To LB, Hughes TP, Roberts MM, Lynch K, Vernon-Roberts B, Zannettino AC. Long-term imatinib therapy promotes bone formation in CML patients. Blood. 111: 2538-47. PMID 18042796 DOI: 10.1182/blood-2007-07-104281 |
0.202 |
|
| 2008 |
Ross DM, Hughes TP. How complete is "complete" molecular response in imatinib-treated chronic myeloid leukemia? Leukemia and Lymphoma. 49: 1230-1231. PMID 18604711 DOI: 10.1080/10428190802158461 |
0.202 |
|
| 2012 |
Nieborowska-Skorska M, Kopinski PK, Ray R, Hoser G, Ngaba D, Flis S, Cramer K, Reddy MM, Koptyra M, Penserga T, Glodkowska-Mrowka E, Bolton E, Holyoake TL, Eaves CJ, Cerny-Reiterer S, ... ... Hughes TP, et al. Rac2-MRC-cIII-generated ROS cause genomic instability in chronic myeloid leukemia stem cells and primitive progenitors. Blood. 119: 4253-63. PMID 22411871 DOI: 10.1182/Blood-2011-10-385658 |
0.197 |
|
| 2011 |
Stein AM, Bottino D, Modur V, Branford S, Kaeda J, Goldman JM, Hughes TP, Radich JP, Hochhaus A. BCR-ABL transcript dynamics support the hypothesis that leukemic stem cells are reduced during imatinib treatment. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 17: 6812-21. PMID 21903771 DOI: 10.1158/1078-0432.Ccr-11-0396 |
0.197 |
|
| 2019 |
Hughes TP, Mauro MJ, Cortes JE, Minami H, Rea D, DeAngelo DJ, Breccia M, Goh YT, Talpaz M, Hochhaus A, le Coutre P, Ottmann O, Heinrich MC, Steegmann JL, Deininger MWN, et al. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure. The New England Journal of Medicine. 381: 2315-2326. PMID 31826340 DOI: 10.1056/Nejmoa1902328 |
0.196 |
|
| 2010 |
Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, ... ... Hughes TP, et al. Phase III, randomized, open-label study of daily imatinib mesylate 400 mg versus 800 mg in patients with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase using molecular end points: tyrosine kinase inhibitor optimization and selectivity study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 28: 424-30. PMID 20008622 DOI: 10.1200/Jco.2009.25.3724 |
0.195 |
|
| 2020 |
Irani YD, Hughes A, Clarson J, Kok CH, Shanmuganathan N, White DL, Yeung DT, Ross DM, Hughes TP, Yong ASM. Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cells. British Journal of Haematology. PMID 32352166 DOI: 10.1111/bjh.16718 |
0.195 |
|
| 2010 |
Branford S, Hughes TP. Practical considerations for monitoring patients with chronic myeloid leukemia. Seminars in Hematology. 47: 327-34. PMID 20875549 DOI: 10.1053/j.seminhematol.2010.06.007 |
0.194 |
|
| 2012 |
Larson RA, Yin OQ, Hochhaus A, Saglio G, Clark RE, Nakamae H, Gallagher NJ, Demirhan E, Hughes TP, Kantarjian HM, le Coutre PD. Population pharmacokinetic and exposure-response analysis of nilotinib in patients with newly diagnosed Ph+ chronic myeloid leukemia in chronic phase. European Journal of Clinical Pharmacology. 68: 723-33. PMID 22207416 DOI: 10.1007/s00228-011-1200-7 |
0.194 |
|
| 2014 |
Dhagat U, Woodcock J, Tiong C, Holien J, Coolen C, Broughton S, Pitson S, Hughes T, Lopez A, Parker M. Structural studies on 14-3-3ζ: Compounds that target the dimer interface Acta Crystallographica Section A. 70. DOI: 10.1107/S2053273314091918 |
0.194 |
|
| 2022 |
Adnan Awad S, Brück O, Shanmuganathan N, Jarvinen T, Lähteenmäki H, Klievink J, Ibrahim H, Kytölä S, Koskenvesa P, Hughes TP, Branford S, Kankainen M, Mustjoki S. Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuation. Blood Cancer Journal. 12: 69. PMID 35443743 DOI: 10.1038/s41408-022-00667-9 |
0.192 |
|
| 2017 |
Marum JE, Yeung DT, Purins L, Reynolds J, Parker WT, Stangl D, Wang PPS, Price DJ, Tuke J, Schreiber AW, Scott HS, Hughes TP, Branford S. ASXL1 and BIM germ line variants predict response and identify CML patients with the greatest risk of imatinib failure. Blood Advances. 1: 1369-1381. PMID 29296778 DOI: 10.1182/bloodadvances.2017006825 |
0.192 |
|
| 2021 |
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, et al. Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. PMID 33414482 DOI: 10.1038/s41375-020-01111-2 |
0.191 |
|
| 2017 |
Pagani IS, Kok CH, Saunders VA, Van der Hoek MB, Heatley SL, Schwarer AP, Hahn CN, Hughes TP, White DL, Ross DM. A Method for Next-Generation Sequencing of Paired Diagnostic and Remission Samples to Detect Mitochondrial DNA Mutations Associated with Leukemia. The Journal of Molecular Diagnostics : Jmd. PMID 28732215 DOI: 10.1016/j.jmoldx.2017.05.009 |
0.191 |
|
| 2016 |
Eadie LN, Hughes TP, White DL. ABCB1 Overexpression Is a Key Initiator of Resistance to Tyrosine Kinase Inhibitors in CML Cell Lines. Plos One. 11: e0161470. PMID 27536777 DOI: 10.1371/journal.pone.0161470 |
0.19 |
|
| 2012 |
Branford S, Yeung DT, Prime JA, Choi SY, Bang JH, Park JE, Kim DW, Ross DM, Hughes TP. BCR-ABL1 doubling times more reliably assess the dynamics of CML relapse compared with the BCR-ABL1 fold rise: implications for monitoring and management. Blood. 119: 4264-71. PMID 22431575 DOI: 10.1182/blood-2011-11-393041 |
0.19 |
|
| 2020 |
Pagani IS, Dang P, Saunders VA, Braley J, Thieleke A, Branford S, Hughes TP, Ross DM. Clinical utility of genomic DNA Q-PCR for the monitoring of a patient with atypical e19a2 transcripts in chronic myeloid leukemia. Leukemia & Lymphoma. 1-3. PMID 32508223 DOI: 10.1080/10428194.2020.1772476 |
0.189 |
|
| 2009 |
Guilhot F, Hughes TP, Kim DW, Cortes JE, Khoury HJ. Dasatinib treatment for philadelphia chromosome-positive leukemias Cancer. 115: 1381-1394. PMID 19195046 DOI: 10.1002/cncr.24155 |
0.187 |
|
| 2002 |
Branford S, Hughes TP, Rudzki Z. Dual transcription of b2a2 and b3a2 BCR-ABL transcripts in chronic myeloid leukaemia is confined to patients with a linked polymorphism within the BCR gene. British Journal of Haematology. 117: 875-7. PMID 12060123 DOI: 10.1046/j.1365-2141.2002.03508.x |
0.186 |
|
| 2022 |
Lu L, Kok CH, Dang P, Branford S, Saunders VA, Shanmuganathan N, Ross DM, Hughes TP, Yeung DTO. Highly sensitive droplet digital polymerase chain reaction for BCR::ABL1 messenger RNA identifies patients with chronic myeloid leukaemia with a low probability of achieving treatment-free remission. British Journal of Haematology. PMID 35620965 DOI: 10.1111/bjh.18277 |
0.186 |
|
| 2015 |
Ong J, Yeung D, Filshie R, Hughes TP, Nandurkar H. Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia. International Journal of Hematology. 102: 639-42. PMID 26134364 DOI: 10.1007/s12185-015-1824-y |
0.185 |
|
| 2020 |
Ross DM, Hughes TP. There is a best duration of deep molecular response for treatment-free remission, but it is patient-specific, and that is the challenge. British Journal of Haematology. PMID 33169882 DOI: 10.1111/bjh.17111 |
0.185 |
|
| 2015 |
Yeung DT, Moulton DJ, Heatley SL, Nievergall E, Dang P, Braley J, Branford S, Moore S, Mullighan CG, Hughes TP, White DL. Relapse of BCR-ABL1-like ALL mediated by the ABL1 kinase domain mutation T315I following initial response to dasatinib treatment. Leukemia. 29: 230-2. PMID 25179732 DOI: 10.1038/leu.2014.256 |
0.185 |
|
| 2017 |
Sadras T, Heatley SL, Kok CH, Dang P, Galbraith KM, McClure BJ, Muskovic W, Venn NC, Moore S, Osborn M, Revesz T, Moore AS, Hughes TP, Yeung D, Sutton R, et al. Differential expression of MUC4, GPR110 and IL2RA defines two groups of CRLF2-rearranged acute lymphoblastic leukemia patients with distinct secondary lesions. Cancer Letters. PMID 28866095 DOI: 10.1016/j.canlet.2017.08.034 |
0.184 |
|
| 2001 |
Borg MB, Hughes T, Tilley C. Renal toxicity after total body irradiation European Journal of Cancer. 37. DOI: 10.1016/S0959-8049(01)81230-2 |
0.184 |
|
| 2005 |
Dewar AL, Zannettino ACW, Hughes TP, Lyons AB. Inhibition of c-fms by imatinib: Expanding the spectrum of treatment Cell Cycle. 4: 851-853. PMID 15917650 |
0.183 |
|
| 2011 |
Tang C, Schafranek L, Watkins DB, Parker WT, Moore S, Prime JA, White DL, Hughes TP. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways. Leukemia & Lymphoma. 52: 2139-47. PMID 21718141 DOI: 10.3109/10428194.2011.591013 |
0.18 |
|
| 2009 |
Branford S, Melo JV, Hughes TP. Selecting optimal second-line tyrosine kinase inhibitor therapy for chronic myeloid leukemia patients after imatinib failure: does the BCR-ABL mutation status really matter? Blood. 114: 5426-35. PMID 19880502 DOI: 10.1182/blood-2009-08-215939 |
0.18 |
|
| 2007 |
Hughes T, Rusten TE. Origin and evolution of self-consumption Advances in Experimental Medicine and Biology. 607: 111-118. PMID 17977463 DOI: 10.1007/978-0-387-74021-8-9 |
0.178 |
|
| 2023 |
Fornes O, Jia A, Kuehn HS, Min Q, Pannicke U, Schleussner N, Thouenon R, Yu Z, de Los Angeles Astbury M, Biggs CM, Galicchio M, Garcia-Campos JA, Gismondi S, Gonzalez Villarreal G, Hildebrand KJ, ... ... Hughes TR, et al. A multimorphic mutation in IRF4 causes human autosomal dominant combined immunodeficiency. Science Immunology. 8: eade7953. PMID 36662884 DOI: 10.1126/sciimmunol.ade7953 |
0.178 |
|
| 2008 |
Mullighan CG, Miller CB, Radtke I, Phillips LA, Dalton J, Ma J, White D, Hughes TP, Le Beau MM, Pui CH, Relling MV, Shurtleff SA, Downing JR. BCR-ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros. Nature. 453: 110-4. PMID 18408710 DOI: 10.1038/nature06866 |
0.178 |
|
| 2024 |
Holmgren A, Akkouh I, O'Connell KS, Osete JR, Bjørnstad PM, Djurovic S, Hughes T. Bipolar patients display stoichiometric imbalance of gene expression in post-mortem brain samples. Molecular Psychiatry. PMID 38351171 DOI: 10.1038/s41380-023-02398-0 |
0.178 |
|
| 2008 |
Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 14: 3881-8. PMID 18559609 DOI: 10.1158/1078-0432.CCR-07-5095 |
0.177 |
|
| 2010 |
Engler JR, Frede A, Saunders V, Zannettino A, White DL, Hughes TP. The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells. Blood. 116: 2776-8. PMID 20634379 DOI: 10.1182/blood-2010-01-267013 |
0.177 |
|
| 2017 |
Rasko JEJ, Hughes TP. First Approved Kinase Inhibitor for AML. Cell. 171: 981. PMID 29149610 DOI: 10.1016/j.cell.2017.11.007 |
0.176 |
|
| 2017 |
Hughes A, Clarson J, Tang C, Vidovic L, White DL, Hughes TP, Yong AS. CML patients with deep molecular responses to TKI have restored immune effectors, decreased PD-1 and immune suppressors. Blood. PMID 28049640 DOI: 10.1182/blood-2016-10-745992 |
0.175 |
|
| 2003 |
Frost MJ, Ferrao PT, Hughes TP, Ashman LK. Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant. Molecular Cancer Therapeutics. 1: 1115-24. PMID 12481435 |
0.175 |
|
| 2012 |
Guilhot F, Hughes TP, Cortes J, Druker BJ, Baccarani M, Gathmann I, Hayes M, Granvil C, Wang Y. Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity Trial. Haematologica. 97: 731-8. PMID 22315495 DOI: 10.3324/Haematol.2011.045666 |
0.175 |
|
| 2021 |
García-Montolio M, Ballaré C, Blanco E, Gutiérrez A, Aranda S, Gómez A, Kok CH, Yeung DT, Hughes TP, Vizán P, Di Croce L. Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia Cells. Frontiers in Cell and Developmental Biology. 9: 655201. PMID 33996816 DOI: 10.3389/fcell.2021.655201 |
0.174 |
|
| 2022 |
Kutyna MM, Kok CH, Lim Y, Tran ENH, Campbell D, Paton S, Thompson-Peach C, Lim K, Cakouros D, Arthur A, Hughes T, Kumar S, Thomas D, Gronthos S, Hiwase DK. A senescence stress secretome is a hallmark of therapy-related myeloid neoplasm stromal tissue occurring soon after cytotoxic exposure. Leukemia. PMID 36038666 DOI: 10.1038/s41375-022-01686-y |
0.174 |
|
| 2023 |
Leow BCS, Kok CH, Yeung DT, Hughes TP, White DL, Eadie LN. The acquisition order of leukemic drug resistance mutations is directed by the selective fitness associated with each resistance mechanism. Scientific Reports. 13: 13110. PMID 37567965 DOI: 10.1038/s41598-023-40279-2 |
0.172 |
|
| 2013 |
Vandyke K, Fitter S, Drew J, Fukumoto S, Schultz CG, Sims NA, Yeung DT, Hughes TP, Zannettino AC. Prospective histomorphometric and DXA evaluation of bone remodeling in imatinib-treated CML patients: evidence for site-specific skeletal effects. The Journal of Clinical Endocrinology and Metabolism. 98: 67-76. PMID 23144472 DOI: 10.1210/jc.2012-2426 |
0.17 |
|
| 2018 |
Eadie LN, Dang P, Goyne JM, Hughes TP, White DL. ABCC6 plays a significant role in the transport of nilotinib and dasatinib, and contributes to TKI resistance in vitro, in both cell lines and primary patient mononuclear cells. Plos One. 13: e0192180. PMID 29385210 DOI: 10.1371/journal.pone.0192180 |
0.169 |
|
| 2006 |
Sopko R, Huang D, Preston N, Chua G, Papp B, Kafadar K, Snyder M, Oliver SG, Cyert M, Hughes TR, Boone C, Andrews B. Mapping pathways and phenotypes by systematic gene overexpression. Molecular Cell. 21: 319-30. PMID 16455487 DOI: 10.1016/J.Molcel.2005.12.011 |
0.169 |
|
| 2010 |
Fitter S, Vandyke K, Schultz CG, White D, Hughes TP, Zannettino AC. Plasma adiponectin levels are markedly elevated in imatinib-treated chronic myeloid leukemia (CML) patients: a mechanism for improved insulin sensitivity in type 2 diabetic CML patients? The Journal of Clinical Endocrinology and Metabolism. 95: 3763-7. PMID 20466781 DOI: 10.1210/jc.2010-0086 |
0.169 |
|
| 2015 |
Hughes T, Klairmont M, Broucek J, Iodice G, Basu S, Kaufman HL. The prognostic significance of stable disease following high-dose interleukin-2 (IL-2) treatment in patients with metastatic melanoma and renal cell carcinoma. Cancer Immunology, Immunotherapy : Cii. 64: 459-65. PMID 25603775 DOI: 10.1007/S00262-014-1652-6 |
0.168 |
|
| 2020 |
Mauro MJ, Hughes TP. Asciminib in Relapsed Chronic Myeloid Leukemia. Reply. The New England Journal of Medicine. 382: 1379. PMID 32242376 DOI: 10.1056/NEJMc2000116#sa2 |
0.168 |
|
| 2018 |
Eadie LN, Hughes TP, White DL. Patients with low OCT-1 activity and high ABCB1 fold rise have poor long-term outcomes in response to tyrosine kinase inhibitor therapy. Leukemia. PMID 29654270 DOI: 10.1038/s41375-018-0101-5 |
0.168 |
|
| 2015 |
Bartley PA, Latham S, Budgen B, Ross DM, Hughes E, Branford S, White D, Hughes TP, Morley AA. A DNA real-time quantitative PCR method suitable for routine monitoring of low levels of minimal residual disease in chronic myeloid leukemia. The Journal of Molecular Diagnostics : Jmd. 17: 185-92. PMID 25554588 DOI: 10.1016/j.jmoldx.2014.10.002 |
0.166 |
|
| 2021 |
Krull F, Akkouh I, Hughes T, Bettella F, Athanasiu L, Smeland OB, O'Connell KS, Brattbakk HR, Steen VM, Steen NE, Djurovic S, Andreassen OA. Dose-dependent transcriptional effects of lithium and adverse effect burden in a psychiatric cohort. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 110408. PMID 34320404 DOI: 10.1016/j.pnpbp.2021.110408 |
0.164 |
|
| 2015 |
Hughes T, Klairmont M, Sharfman WH, Kaufman HL. Interleukin-2, Ipilimumab, and Anti-PD-1: Clinical Management and the Evolving Role of Immunotherapy for the Treatment of Patients With Metastatic Melanoma. Cancer Biology & Therapy. 0. PMID 26418961 DOI: 10.1080/15384047.2015.1095401 |
0.164 |
|
| 2024 |
Kantarjian H, Branford S, Breccia M, Cortes J, Haddad FG, Hochhaus A, Hughes T, Issa GC, Jabbour E, Nicolini FE, Sasaki K, Xavier-Mahon F. Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia? Leukemia. PMID 38531949 DOI: 10.1038/s41375-024-02229-3 |
0.163 |
|
| 2021 |
Osete JR, Akkouh IA, de Assis DR, Szabo A, Frei E, Hughes T, Smeland OB, Steen NE, Andreassen OA, Djurovic S. Lithium increases mitochondrial respiration in iPSC-derived neural precursor cells from lithium responders. Molecular Psychiatry. PMID 34075196 DOI: 10.1038/s41380-021-01164-4 |
0.163 |
|
| 2022 |
Shanmuganathan N, Wadham C, Thomson D, Shahrin NH, Vignaud C, Obourn V, Chaturvedi S, Yang F, Feng J, Saunders V, Kok CH, Yeung D, King RM, Kenyon RR, Lin M, ... ... Hughes T, et al. RNA-based targeted gene sequencing improves the diagnostic yield of mutant detection in chronic myeloid leukemia. The Journal of Molecular Diagnostics : Jmd. PMID 35550185 DOI: 10.1016/j.jmoldx.2022.04.004 |
0.162 |
|
| 2012 |
Hiwase DK, Hughes TP. Sudden blast crisis in chronic myeloid leukemia treated with tyrosine kinase inhibitors. Leukemia & Lymphoma. 53: 1251-2. PMID 22475357 DOI: 10.3109/10428194.2012.682314 |
0.162 |
|
| 2015 |
Chutake YK, Costello WN, Lam CC, Parikh AC, Hughes TT, Michalopulos MG, Pook MA, Bidichandani SI. FXN Promoter Silencing in the Humanized Mouse Model of Friedreich Ataxia. Plos One. 10: e0138437. PMID 26393353 DOI: 10.1371/Journal.Pone.0138437 |
0.162 |
|
| 2023 |
Irani YD, Kok CH, Clarson J, Shanmuganathan N, Branford S, Yeung DT, Ross DM, Hughes TP, Yong AS. Association of TIM-3 checkpoint receptor expression on T cells with treatment-free remission in chronic myeloid leukemia. Blood Advances. PMID 36622326 DOI: 10.1182/bloodadvances.2022008854 |
0.161 |
|
| 2008 |
Hughes TR, Roth FP. A race through the maze of genomic evidence. Genome Biology. 9: S1. PMID 18613945 DOI: 10.1186/Gb-2008-9-S1-S1 |
0.161 |
|
| 2014 |
Nievergall E, Ramshaw HS, Yong AS, Biondo M, Busfield SJ, Vairo G, Lopez AF, Hughes TP, White DL, Hiwase DK. Monoclonal antibody targeting of IL-3 receptor α with CSL362 effectively depletes CML progenitor and stem cells. Blood. 123: 1218-28. PMID 24363400 DOI: 10.1182/blood-2012-12-475194 |
0.161 |
|
| 2018 |
Lu L, Kok CH, Saunders VA, Wang J, McLean JA, Hughes TP, White DL. Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant + cell lines. Oncotarget. 9: 34735-34747. PMID 30410673 DOI: 10.18632/oncotarget.26187 |
0.161 |
|
| 2023 |
Mazzarino M, Cetin E, Bartosova M, Marinovic I, Ipseiz N, Hughes TR, Schmitt CP, Ramji DP, Labéta MO, Raby AC. Therapeutic targeting of chronic kidney disease-associated DAMPs differentially contributing to vascular pathology. Frontiers in Immunology. 14: 1240679. PMID 37849759 DOI: 10.3389/fimmu.2023.1240679 |
0.159 |
|
| 2005 |
Frey BJ, Mohammad N, Morris QD, Zhang W, Robinson MD, Mnaimneh S, Chang R, Pan Q, Sat E, Rossant J, Bruneau BG, Aubin JE, Blencowe BJ, Hughes TR. Genome-wide analysis of mouse transcripts using exon microarrays and factor graphs. Nature Genetics. 37: 991-6. PMID 16127451 DOI: 10.1038/Ng1630 |
0.158 |
|
| 2006 |
White DL, Saunders VA, Dang P, Engler J, Zannettino AC, Cambareri AC, Quinn SR, Manley PW, Hughes TP. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood. 108: 697-704. PMID 16597591 DOI: 10.1182/blood-2005-11-4687 |
0.158 |
|
| 2016 |
Latham S, Bartley PA, Budgen B, Ross DM, Hughes E, Branford S, White D, Hughes TP, Morley AA. BCR-ABL1 expression, RT-qPCR and treatment decisions in chronic myeloid leukaemia. Journal of Clinical Pathology. PMID 26837312 DOI: 10.1136/jclinpath-2015-203538 |
0.157 |
|
| 2006 |
Yu L, Peña Castillo L, Mnaimneh S, Hughes TR, Brown GW. A survey of essential gene function in the yeast cell division cycle. Molecular Biology of the Cell. 17: 4736-47. PMID 16943325 DOI: 10.1091/Mbc.E06-04-0368 |
0.157 |
|
| 2007 |
Peña-Castillo L, Hughes TR. Why are there still over 1000 uncharacterized yeast genes? Genetics. 176: 7-14. PMID 17435240 DOI: 10.1534/genetics.107.074468 |
0.156 |
|
| 2013 |
Hiwase DK, Saunders VA, Nievergall E, Ross DD, White DL, Hughes TP. Dasatinib targets chronic myeloid leukemia-CD34+ progenitors as effectively as it targets mature cells. Haematologica. 98: 896-900. PMID 23065516 DOI: 10.3324/haematol.2012.070268 |
0.156 |
|
| 2018 |
Tvorogov D, Thomas D, Liau NPD, Dottore M, Barry EF, Lathi M, Kan WL, Hercus TR, Stomski F, Hughes TP, Tergaonkar V, Parker MW, Ross DM, Majeti R, Babon JJ, et al. Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis. Science Advances. 4: eaat3834. PMID 30498775 DOI: 10.1126/Sciadv.Aat3834 |
0.156 |
|
| 2016 |
Barratt DT, Cox HK, Menelaou A, Yeung DT, White DL, Hughes TP, Somogyi AA. CYP2C8 Genotype Significantly Alters Imatinib Metabolism in Chronic Myeloid Leukaemia Patients. Clinical Pharmacokinetics. PMID 27995529 DOI: 10.1007/s40262-016-0494-0 |
0.156 |
|
| 2008 |
Blake S, Hughes TP, Mayrhofer G, Lyons AB. The Src/ABL kinase inhibitor dasatinib (BMS-354825) inhibits function of normal human T-lymphocytes in vitro Clinical Immunology. 127: 330-339. PMID 18395492 DOI: 10.1016/j.clim.2008.02.006 |
0.156 |
|
| 2015 |
Schafranek L, Nievergall E, Powell JA, Hiwase DK, Leclercq T, Hughes TP, White DL. Sustained inhibition of STAT5, but not JAK2, is essential for TKI-induced cell death in chronic myeloid leukemia. Leukemia. 29: 76-85. PMID 24813920 DOI: 10.1038/leu.2014.156 |
0.155 |
|
| 2001 |
Hughes TR, Shoemaker DD. DNA microarrays for expression profiling. Current Opinion in Chemical Biology. 5: 21-5. PMID 11166643 DOI: 10.1016/S1367-5931(00)00163-0 |
0.155 |
|
| 2015 |
Koues OI, Kowalewski RA, Chang LW, Pyfrom SC, Schmidt JA, Luo H, Sandoval LE, Hughes TB, Bednarski JJ, Cashen AF, Payton JE, Oltz EM. Enhancer sequence variants and transcription-factor deregulation synergize to construct pathogenic regulatory circuits in B-cell lymphoma. Immunity. 42: 186-98. PMID 25607463 DOI: 10.1016/J.Immuni.2014.12.021 |
0.154 |
|
| 2005 |
Dewar AL, Cambareri AC, Zannettino ACW, Miller BL, Doherty KV, Hughes TP, Bruce Lyons A. Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib Blood. 105: 3127-3132. PMID 15637141 DOI: 10.1182/blood-2004-10-3967 |
0.154 |
|
| 2019 |
Shanmuganathan N, Braley JA, Yong AS, Hiwase DK, Yeung DT, Ross DM, Hughes TP, Branford S. Modelling the safe minimum frequency of molecular monitoring for CML patients attempting treatment-free remission. Blood. PMID 30967368 DOI: 10.1182/blood.2019000120 |
0.153 |
|
| 2021 |
Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, et al. Correction to: Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. PMID 34108614 DOI: 10.1038/s41375-021-01306-1 |
0.153 |
|
| 2009 |
Kainth P, Sassi HE, Peña-Castillo L, Chua G, Hughes TR, Andrews B. Comprehensive genetic analysis of transcription factor pathways using a dual reporter gene system in budding yeast. Methods (San Diego, Calif.). 48: 258-64. PMID 19269327 DOI: 10.1016/J.Ymeth.2009.02.015 |
0.153 |
|
| 1997 |
Hughes TR, Morris DK, Salinger A, Walcott N, Nugent CI, Lundblad V. The role of the EST genes in yeast telomere replication. Ciba Foundation Symposium. 211: 41-7; discussion 47-. PMID 9524750 DOI: 10.1002/9780470515433.ch4 |
0.151 |
|
| 2000 |
Hughes TR, Marton MJ, Jones AR, Roberts CJ, Stoughton R, Armour CD, Bennett HA, Coffey E, Dai H, He YD, Kidd MJ, King AM, Meyer MR, Slade D, Lum PY, et al. Functional discovery via a compendium of expression profiles. Cell. 102: 109-26. PMID 10929718 |
0.15 |
|
| 2015 |
Xiong HY, Alipanahi B, Lee LJ, Bretschneider H, Merico D, Yuen RK, Hua Y, Gueroussov S, Najafabadi HS, Hughes TR, Morris Q, Barash Y, Krainer AR, Jojic N, Scherer SW, et al. RNA splicing. The human splicing code reveals new insights into the genetic determinants of disease. Science (New York, N.Y.). 347: 1254806. PMID 25525159 DOI: 10.1126/Science.1254806 |
0.149 |
|
| 2019 |
Ross DM, Pagani IS, Irani YD, Clarson J, Leclercq T, Dang P, McLean J, Saunders VA, Carne L, Reynolds J, Ritchie DS, White DL, Branford S, Hughes TP, Yong ASM. Lenalidomide maintenance treatment after imatinib discontinuation: results of a phase 1 clinical trial in chronic myeloid leukaemia. British Journal of Haematology. PMID 30916385 DOI: 10.1111/bjh.15894 |
0.148 |
|
| 2010 |
van Bakel H, Nislow C, Blencowe BJ, Hughes TR. Most "dark matter" transcripts are associated with known genes. Plos Biology. 8: e1000371. PMID 20502517 DOI: 10.1371/Journal.Pbio.1000371 |
0.148 |
|
| 2003 |
Mead JR, Hughes TR, Irvine SA, Singh NN, Ramji DP. Interferon-γ stimulates the expression of the inducible cAMP early repressor in macrophages through the activation of casein kinase 2. A potentially novel pathway for interferon-γ-mediated inhibition of gene transcription Journal of Biological Chemistry. 278: 17741-17751. PMID 12609974 DOI: 10.1074/jbc.M301602200 |
0.148 |
|
| 2008 |
Willis IM, Chua G, Tong AH, Brost RL, Hughes TR, Boone C, Moir RD. Genetic interactions of MAF1 identify a role for Med20 in transcriptional repression of ribosomal protein genes. Plos Genetics. 4: e1000112. PMID 18604275 DOI: 10.1371/Journal.Pgen.1000112 |
0.148 |
|
| 2017 |
Wang J, Lu L, Kok CH, Saunders VA, Goyne JM, Dang P, Leclercq TM, Hughes TP, White DL. Increased peroxisome proliferator-activated receptor-gamma activity reduces imatinib uptake and efficacy in chronic myeloid leukemia mononuclear cells. Haematologica. PMID 28154092 DOI: 10.3324/haematol.2016.153270 |
0.147 |
|
| 2021 |
Kelly L, Dreher D, Kim G, Hughes T, Sabouri AS. Placement of a Peripherally Inserted Central Catheter in a Prone Patient With COVID-19: Feasibility and Case Report. Journal of Infusion Nursing : the Official Publication of the Infusion Nurses Society. 44: 199-202. PMID 34197349 DOI: 10.1097/NAN.0000000000000430 |
0.147 |
|
| 2009 |
Fraser CK, Lousberg EL, Kumar R, Hughes TP, Diener KR, Hayball JD. Dasatinib inhibits the secretion of TNF-alpha following TLR stimulation in vitro and in vivo. Experimental Hematology. 37: 1435-44. PMID 19786067 DOI: 10.1016/j.exphem.2009.09.007 |
0.147 |
|
| 2007 |
Hughes T. Is drug treatment superior to allografting as first-line therapy in chronic myeloid leukemia? Nature Clinical Practice. Oncology. 5: 14-5. PMID 17940526 DOI: 10.1038/ncponc0983 |
0.146 |
|
| 2023 |
Torsvik A, Brattbakk HR, Trentani A, Holdhus R, Stansberg C, Bartz-Johannessen CA, Hughes T, Steen NE, Melle I, Djurovic S, Andreassen OA, Steen VM. Patients with schizophrenia and bipolar disorder display a similar global gene expression signature in whole blood that reflects elevated proportion of immature neutrophil cells with association to lipid changes. Translational Psychiatry. 13: 147. PMID 37147304 DOI: 10.1038/s41398-023-02442-1 |
0.146 |
|
| 2006 |
Chua G, Morris QD, Sopko R, Robinson MD, Ryan O, Chan ET, Frey BJ, Andrews BJ, Boone C, Hughes TR. Identifying transcription factor functions and targets by phenotypic activation. Proceedings of the National Academy of Sciences of the United States of America. 103: 12045-50. PMID 16880382 DOI: 10.1073/Pnas.0605140103 |
0.145 |
|
| 2005 |
Frey BJ, Morris QD, Zhang W, Mohammad N, Hughes TR. Genrate: a generative model that finds and scores new genes and exons in genomic microarray data. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing. 495-506. PMID 15759654 |
0.144 |
|
| 2006 |
Dewar AL, Farrugia AN, Condina MR, To LB, Hughes TP, Vernon-Roberts B, Zannettino ACW. Imatinib as a potential antiresorptive therapy for bone disease Blood. 107: 4334-4337. PMID 16449525 DOI: 10.1182/blood-2005-09-3568 |
0.143 |
|
| 2018 |
Eadie LN, Saunders VA, Branford S, White DL, Hughes TP. The new allosteric inhibitor asciminib is susceptible to resistance mediated by ABCB1 and ABCG2 overexpression. Oncotarget. 9: 13423-13437. PMID 29568367 DOI: 10.18632/oncotarget.24393 |
0.142 |
|
| 2006 |
Lee LJ, Hughes TR, Frey BJ. How many new genes are there? Science (New York, N.Y.). 311: 1709-11; author repl. PMID 16556823 DOI: 10.1126/Science.311.5768.1709B |
0.142 |
|
| 2016 |
Towner LD, Wheat RA, Hughes TR, Morgan BP. Complement membrane attack and tumourigenesis: a systems biology approach. The Journal of Biological Chemistry. PMID 27226542 DOI: 10.1074/jbc.M115.708446 |
0.142 |
|
| 2007 |
Tadros W, Goldman AL, Babak T, Menzies F, Vardy L, Orr-Weaver T, Hughes TR, Westwood JT, Smibert CA, Lipshitz HD. SMAUG is a major regulator of maternal mRNA destabilization in Drosophila and its translation is activated by the PAN GU kinase. Developmental Cell. 12: 143-55. PMID 17199047 DOI: 10.1016/J.Devcel.2006.10.005 |
0.141 |
|
| 2000 |
Roberts CJ, Nelson B, Marton MJ, Stoughton R, Meyer MR, Bennett HA, He YD, Dai H, Walker WL, Hughes TR, Tyers M, Boone C, Friend SH. Signaling and circuitry of multiple MAPK pathways revealed by a matrix of global gene expression profiles Science. 287: 873-880. PMID 10657304 DOI: 10.1126/Science.287.5454.873 |
0.141 |
|
| 2022 |
Holmgren A, Hansson L, Bjerkaas-Kjeldal K, Impellizzeri AAR, Gilfillan GD, Djurovic S, Hughes T. Mapping the expression of an ANK3 isoform associated with bipolar disorder in the human brain. Translational Psychiatry. 12: 45. PMID 35091539 DOI: 10.1038/s41398-022-01784-6 |
0.14 |
|
| 2010 |
Fraser CK, Lousberg EL, Guerin LR, Hughes TP, Brown MP, Diener KR, Hayball JD. Dasatinib alters the metastatic phenotype of B16-OVA melanoma in vivo. Cancer Biology & Therapy. 10: 715-27. PMID 20676039 DOI: 10.4161/cbt.10.7.12926 |
0.139 |
|
| 2013 |
Thomas D, Powell JA, Green BD, Barry EF, Ma Y, Woodcock J, Fitter S, Zannettino AC, Pitson SM, Hughes TP, Lopez AF, Shepherd PR, Wei AH, Ekert PG, Guthridge MA. Protein kinase activity of phosphoinositide 3-kinase regulates cytokine-dependent cell survival. Plos Biology. 11: e1001515. PMID 23526884 DOI: 10.1371/Journal.Pbio.1001515 |
0.139 |
|
| 2004 |
Mnaimneh S, Davierwala AP, Haynes J, Moffat J, Peng WT, Zhang W, Yang X, Pootoolal J, Chua G, Lopez A, Trochesset M, Morse D, Krogan NJ, Hiley SL, Li Z, ... ... Hughes TR, et al. Exploration of essential gene functions via titratable promoter alleles. Cell. 118: 31-44. PMID 15242642 DOI: 10.1016/J.Cell.2004.06.013 |
0.138 |
|
| 2004 |
Zhang W, Morris QD, Chang R, Shai O, Bakowski MA, Mitsakakis N, Mohammad N, Robinson MD, Zirngibl R, Somogyi E, Laurin N, Eftekharpour E, Sat E, Grigull J, Pan Q, ... ... Hughes TR, et al. The functional landscape of mouse gene expression. Journal of Biology. 3: 21. PMID 15588312 DOI: 10.1186/Jbiol16 |
0.138 |
|
| 2006 |
Frey BJ, Morris QD, Hughes TR. GenRate: a generative model that reveals novel transcripts in genome-tiling microarray data. Journal of Computational Biology : a Journal of Computational Molecular Cell Biology. 13: 200-14. PMID 16597235 DOI: 10.1089/Cmb.2006.13.200 |
0.138 |
|
| 1997 |
Lingner J, Cech TR, Hughes TR, Lundblad V. Three Ever Shorter Telomere (EST) genes are dispensable for in vitro yeast telomerase activity. Proceedings of the National Academy of Sciences of the United States of America. 94: 11190-5. PMID 9326584 DOI: 10.1073/Pnas.94.21.11190 |
0.138 |
|
| 2009 |
Chan ET, Quon GT, Chua G, Babak T, Trochesset M, Zirngibl RA, Aubin J, Ratcliffe MJ, Wilde A, Brudno M, Morris QD, Hughes TR. Conservation of core gene expression in vertebrate tissues. Journal of Biology. 8: 33. PMID 19371447 DOI: 10.1186/Jbiol130 |
0.138 |
|
| 2023 |
Coyle MC, Tajima AM, Leon F, Choksi SP, Yang A, Espinoza S, Hughes TR, Reiter JF, Booth DS, King N. An RFX transcription factor regulates ciliogenesis in the closest living relatives of animals. Current Biology : Cb. PMID 37552984 DOI: 10.1016/j.cub.2023.07.022 |
0.138 |
|
| 2009 |
Fraser CK, Blake SJ, Diener KR, Lyons AB, Brown MP, Hughes TP, Hayball JD. Dasatinib inhibits recombinant viral antigen-specific murine CD4+ and CD8+ T-cell responses and NK-cell cytolytic activity in vitro and in vivo. Experimental Hematology. 37: 256-65. PMID 19056158 DOI: 10.1016/j.exphem.2008.09.013 |
0.138 |
|
| 2019 |
Magomedova L, Tiefenbach J, Zilberman E, Le Billan F, Voisin V, Saikali M, Boivin V, Robitaille M, Gueroussov S, Irimia M, Ray D, Patel R, Xu C, Jeyasuria P, Bader GD, ... Hughes TR, et al. ARGLU1 is a transcriptional coactivator and splicing regulator important for stress hormone signaling and development. Nucleic Acids Research. PMID 30698747 DOI: 10.1093/Nar/Gkz010 |
0.137 |
|
| 2004 |
Jeronimo C, Langelier MF, Zeghouf M, Cojocaru M, Bergeron D, Baali D, Forget D, Mnaimneh S, Davierwala AP, Pootoolal J, Chandy M, Canadien V, Beattie BK, Richards DP, Workman JL, ... Hughes TR, et al. RPAP1, a novel human RNA polymerase II-associated protein affinity purified with recombinant wild-type and mutated polymerase subunits. Molecular and Cellular Biology. 24: 7043-58. PMID 15282305 DOI: 10.1128/Mcb.24.16.7043-7058.2004 |
0.136 |
|
| 2013 |
Hughes TR, de Boer CG. Mapping yeast transcriptional networks. Genetics. 195: 9-36. PMID 24018767 DOI: 10.1534/genetics.113.153262 |
0.136 |
|
| 2009 |
Coughlin DJ, Babak T, Nihranz C, Hughes TR, Engelke DR. Prediction and verification of mouse tRNA gene families Rna Biology. 6. PMID 19246989 DOI: 10.4161/Rna.6.2.8050 |
0.136 |
|
| 2020 |
Turkina A, Wang J, Mathews V, Saydam G, Jung CW, Al Hashmi HH, Yassin M, Le Clanche S, Miljkovic D, Slader C, Hughes TP. TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countries. British Journal of Haematology. PMID 32227648 DOI: 10.1111/bjh.16599 |
0.136 |
|
| 2022 |
de Erausquin GA, Snyder H, Brugha TS, Seshadri S, Carrillo M, Sagar R, Huang Y, Newton C, Tartaglia C, Teunissen C, Håkanson K, Akinyemi R, Prasad K, D'Avossa G, Gonzalez-Aleman G, ... ... Hughes TM, et al. Chronic neuropsychiatric sequelae of SARS-CoV-2: Protocol and methods from the Alzheimer's Association Global Consortium. Alzheimer's & Dementia (New York, N. Y.). 8: e12348. PMID 36185993 DOI: 10.1002/trc2.12348 |
0.136 |
|
| 2010 |
Vandyke K, Fitter S, Dewar AL, Hughes TP, Zannettino AC. Dysregulation of bone remodeling by imatinib mesylate. Blood. 115: 766-74. PMID 19890095 DOI: 10.1182/blood-2009-08-237404 |
0.135 |
|
| 2017 |
Hughes A, Clarson J, Gargett T, Yu W, Brown MP, Lopez AF, Hughes TP, Yong AS. Comment on "KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: Results from a phase 1 study". Leukemia Research. 55: 55-57. PMID 28129558 DOI: 10.1016/j.leukres.2017.01.009 |
0.135 |
|
| 2001 |
Hughes TR, Mao M, Jones AR, Burchard J, Marton MJ, Shannon KW, Lefkowitz SM, Ziman M, Schelter JM, Meyer MR, Kobayashi S, Davis C, Dai H, He YD, Stephaniants SB, et al. Expression profiling using microarrays fabricated by an ink-jet oligonucleotide synthesizer Nature Biotechnology. 19: 342-347. PMID 11283592 DOI: 10.1038/86730 |
0.135 |
|
| 2002 |
Wu LF, Hughes TR, Davierwala AP, Robinson MD, Stoughton R, Altschuler SJ. Large-scale prediction of Saccharomyces cerevisiae gene function using overlapping transcriptional clusters. Nature Genetics. 31: 255-65. PMID 12089522 DOI: 10.1038/ng906 |
0.134 |
|
| 2005 |
Dewar AL, Doherty KV, Hughes TP, Lyons AB. Imatinib inhibits the functional capacity of cultured human monocytes Immunology and Cell Biology. 83: 48-56. PMID 15661041 DOI: 10.1111/j.1440-1711.2004.01296.x |
0.134 |
|
| 2005 |
Babak T, Blencowe BJ, Hughes TR. A systematic search for new mammalian noncoding RNAs indicates little conserved intergenic transcription. Bmc Genomics. 6: 104. PMID 16083503 DOI: 10.1186/1471-2164-6-104 |
0.133 |
|
| 2018 |
Boni AC, Ambrósio DL, Cupertino FB, Montenegro-Montero A, Virgilio S, Freitas FZ, Corrocher FA, Gonçalves RD, Yang A, Weirauch MT, Hughes TR, Larrondo LF, Bertolini MC. Neurospora crassa developmental control mediated by the FLB-3 transcription factor. Fungal Biology. 122: 570-582. PMID 29801802 DOI: 10.1016/J.Funbio.2018.01.004 |
0.132 |
|
| 2001 |
Kockar FT, Foka P, Hughes TR, Kousteni S, Ramji DP. Analysis of the Xenopus laevis CCAAT-enhancer binding protein α gene promoter demonstrates species-specific differences in the mechanisms for both auto-activation and regulation by Sp1 Nucleic Acids Research. 29: 362-372. PMID 11139605 |
0.131 |
|
| 2014 |
de Boer CG, van Bakel H, Tsui K, Li J, Morris QD, Nislow C, Greenblatt JF, Hughes TR. A unified model for yeast transcript definition. Genome Research. 24: 154-66. PMID 24170600 DOI: 10.1101/Gr.164327.113 |
0.131 |
|
| 2010 |
Jaeger SA, Chan ET, Berger MF, Stottmann R, Hughes TR, Bulyk ML. Conservation and regulatory associations of a wide affinity range of mouse transcription factor binding sites. Genomics. 95: 185-95. PMID 20079828 DOI: 10.1016/J.Ygeno.2010.01.002 |
0.131 |
|
| 2023 |
Osete JR, Akkouh IA, Ievglevskyi O, Vandenberghe M, de Assis DR, Ueland T, Kondratskaya E, Holen B, Szabo A, Hughes T, Smeland OB, Steen VM, Andreassen OA, Djurovic S. Transcriptional and functional effects of lithium in bipolar disorder iPSC-derived cortical spheroids. Molecular Psychiatry. PMID 36653674 DOI: 10.1038/s41380-023-01944-0 |
0.13 |
|
| 2004 |
Hughes TR, Robinson MD, Mitsakakis N, Johnston M. The promise of functional genomics: completing the encyclopedia of a cell. Current Opinion in Microbiology. 7: 546-54. PMID 15451511 DOI: 10.1016/J.Mib.2004.08.015 |
0.13 |
|
| 2023 |
Ichikawa DM, Abdin O, Alerasool N, Kogenaru M, Mueller AL, Wen H, Giganti DO, Goldberg GW, Adams S, Spencer JM, Razavi R, Nim S, Zheng H, Gionco C, Clark FT, ... ... Hughes TR, et al. A universal deep-learning model for zinc finger design enables transcription factor reprogramming. Nature Biotechnology. PMID 36702896 DOI: 10.1038/s41587-022-01624-4 |
0.13 |
|
| 2019 |
Lambert SA, Yang AWH, Sasse A, Cowley G, Albu M, Caddick MX, Morris QD, Weirauch MT, Hughes TR. Similarity regression predicts evolution of transcription factor sequence specificity. Nature Genetics. PMID 31133749 DOI: 10.1038/S41588-019-0411-1 |
0.13 |
|
| 2011 |
Stead MB, Marshburn S, Mohanty BK, Mitra J, Pena Castillo L, Ray D, van Bakel H, Hughes TR, Kushner SR. Analysis of Escherichia coli RNase E and RNase III activity in vivo using tiling microarrays. Nucleic Acids Research. 39: 3188-203. PMID 21149258 DOI: 10.1093/nar/gkq1242 |
0.129 |
|
| 2003 |
Nelson B, Kurischko C, Horecka J, Mody M, Nair P, Pratt L, Zougman A, McBroom LD, Hughes TR, Boone C, Luca FC. RAM: a conserved signaling network that regulates Ace2p transcriptional activity and polarized morphogenesis. Molecular Biology of the Cell. 14: 3782-803. PMID 12972564 DOI: 10.1091/Mbc.E03-01-0018 |
0.129 |
|
| 2012 |
De Boer CG, Hughes TR. YeTFaSCo: A database of evaluated yeast transcription factor sequence specificities Nucleic Acids Research. 40: D169-D179. PMID 22102575 DOI: 10.1093/nar/gkr993 |
0.129 |
|
| 2011 |
Huang E, Talukder S, Hughes TR, Curk T, Zupan B, Shaulsky G, Katoh-Kurasawa M. BzpF is a CREB-like transcription factor that regulates spore maturation and stability in Dictyostelium. Developmental Biology. 358: 137-46. PMID 21810415 DOI: 10.1016/j.ydbio.2011.07.017 |
0.129 |
|
| 2007 |
Fagnani M, Barash Y, Ip JY, Misquitta C, Pan Q, Saltzman AL, Shai O, Lee L, Rozenhek A, Mohammad N, Willaime-Morawek S, Babak T, Zhang W, Hughes TR, van der Kooy D, et al. Functional coordination of alternative splicing in the mammalian central nervous system. Genome Biology. 8: R108. PMID 17565696 DOI: 10.1186/Gb-2007-8-6-R108 |
0.128 |
|
| 2018 |
Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, Chen X, Taipale J, Hughes TR, Weirauch MT. The Human Transcription Factors. Cell. 172: 650-665. PMID 29425488 DOI: 10.1016/j.cell.2018.01.029 |
0.128 |
|
| 2022 |
Spruce T, Plass M, Gohr A, Ray D, Martínez de Lagrán M, Rot G, Nóvoa A, Burguera D, Permanyer J, Miret M, Zheng H, Swanson MS, Morris Q, Mallo M, Dierssen M, ... Hughes TR, et al. The X-linked splicing regulator MBNL3 has been co-opted to restrict placental growth in eutherians. Plos Biology. 20: e3001615. PMID 35476669 DOI: 10.1371/journal.pbio.3001615 |
0.128 |
|
| 2018 |
Davis GM, Tu S, Anderson JWT, Colson RN, Gunzburg MJ, Francisco MA, Ray D, Shrubsole SP, Sobotka JA, Seroussi U, Lao RX, Maity T, Wu MZ, McJunkin K, Morris QD, ... Hughes TR, et al. The TRIM-NHL protein NHL-2 is a co-factor in the nuclear and somatic RNAi pathways in . Elife. 7. PMID 30575518 DOI: 10.7554/Elife.35478 |
0.127 |
|
| 2015 |
Ramaglia V, Jackson SJ, Hughes TR, Neal JW, Baker D, Morgan BP. Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Clinical and Experimental Immunology. 180: 432-41. PMID 25619542 DOI: 10.1111/Cei.12595 |
0.127 |
|
| 2008 |
Cheung V, Chua G, Batada NN, Landry CR, Michnick SW, Hughes TR, Winston F. Chromatin- and transcription-related factors repress transcription from within coding regions throughout the Saccharomyces cerevisiae genome. Plos Biology. 6: e277. PMID 18998772 DOI: 10.1371/Journal.Pbio.0060277 |
0.126 |
|
| 2011 |
Gabut M, Samavarchi-Tehrani P, Wang X, Slobodeniuc V, O'Hanlon D, Sung HK, Alvarez M, Talukder S, Pan Q, Mazzoni EO, Nedelec S, Wichterle H, Woltjen K, Hughes TR, Zandstra PW, et al. An alternative splicing switch regulates embryonic stem cell pluripotency and reprogramming. Cell. 147: 132-46. PMID 21924763 DOI: 10.1016/J.Cell.2011.08.023 |
0.126 |
|
| 2023 |
Stepankiw N, Yang AWH, Hughes TR. The human genome contains over a million autonomous exons. Genome Research. 33: 1865-78. PMID 37945377 DOI: 10.1101/gr.277792.123 |
0.126 |
|
| 2008 |
Sandhu C, Hewel JA, Badis G, Talukder S, Liu J, Hughes TR, Emili A. Evaluation of data-dependent versus targeted shotgun proteomic approaches for monitoring transcription factor expression in breast cancer. Journal of Proteome Research. 7: 1529-41. PMID 18311902 DOI: 10.1021/Pr700836Q |
0.125 |
|
| 2014 |
Buckley MA, Shen HC, Mendoza-Fandino GA, Woods NT, Gjyshi A, French J, Lawrenson K, Song H, Tyrer J, Carvalho RS, Valle A, Chen A, Yoder S, Bloom G, Tsai Y, ... ... Hughes TR, et al. Abstract 3285: Functional analysis of the 9p22 locus implicates the transcriptional regulation ofBNC2as a mechanism in ovarian cancer predisposition Cancer Research. 74: 3285-3285. DOI: 10.1158/1538-7445.Am2014-3285 |
0.125 |
|
| 2017 |
Rasmussen HB, Madsen MB, Lyauk YK, Hansen PR, Hughes T. Carboxylesterase 1A2 encoding gene with increased transcription and potential rapid drug metabolism in Asian populations. Drug Metabolism and Personalized Therapy. PMID 28803225 DOI: 10.1515/dmpt-2017-0012 |
0.125 |
|
| 2015 |
Ong J, Yeung D, Filshie R, Hughes TP, Nandurkar H. Imatinib-induced gastric antral vascular ectasia in three patients with chronic myeloid leukaemia International Journal of Hematology. DOI: 10.1007/s12185-015-1824-y |
0.125 |
|
| 2004 |
Chua G, Robinson MD, Morris Q, Hughes TR. Transcriptional networks: reverse-engineering gene regulation on a global scale. Current Opinion in Microbiology. 7: 638-46. PMID 15556037 DOI: 10.1016/j.mib.2004.10.009 |
0.125 |
|
| 2016 |
van der Does HC, Fokkens L, Yang A, Schmidt SM, Langereis L, Lukasiewicz JM, Hughes TR, Rep M. Transcription Factors Encoded on Core and Accessory Chromosomes of Fusarium oxysporum Induce Expression of Effector Genes. Plos Genetics. 12: e1006401. PMID 27855160 DOI: 10.1371/journal.pgen.1006401 |
0.124 |
|
| 2000 |
Hughes TR, Roberts CJ, Dai H, Jones AR, Meyer MR, Slade D, Burchard J, Dow S, Ward TR, Kidd MJ, Friend SH, Marton MJ. Widespread aneuploidy revealed by DNA microarray expression profiling. Nature Genetics. 25: 333-7. PMID 10888885 DOI: 10.1038/77116 |
0.124 |
|
| 2006 |
Zhang W, Walker E, Tamplin OJ, Rossant J, Stanford WL, Hughes TR. Zfp206 regulates ES cell gene expression and differentiation Nucleic Acids Research. 34: 4780-4790. PMID 16971461 DOI: 10.1093/Nar/Gkl631 |
0.123 |
|
| 2009 |
Ross DM, Schafranek L, Hughes TP, Nicola M, Branford S, Score J. Genomic translocation breakpoint sequences are conserved in BCR-ABL1 cell lines despite the presence of amplification Cancer Genetics and Cytogenetics. 189: 138-139. PMID 19215797 DOI: 10.1016/j.cancergencyto.2008.10.010 |
0.122 |
|
| 2007 |
Lee W, Tillo D, Bray N, Morse RH, Davis RW, Hughes TR, Nislow C. A high-resolution atlas of nucleosome occupancy in yeast. Nature Genetics. 39: 1235-44. PMID 17873876 DOI: 10.1038/Ng2117 |
0.122 |
|
| 2001 |
Chandra A, Hughes TR, Nugent CI, Lundblad V. Cdc13 both positively and negatively regulates telomere replication. Genes & Development. 15: 404-14. PMID 11230149 DOI: 10.1101/gad.861001 |
0.121 |
|
| 2008 |
Harris SM, Harvey EJ, Hughes TR, Ramji DP. The interferon-gamma-mediated inhibition of lipoprotein lipase gene transcription in macrophages involves casein kinase 2- and phosphoinositide-3-kinase-mediated regulation of transcription factors Sp1 and Sp3. Cellular Signalling. 20: 2296-301. PMID 18793716 DOI: 10.1016/j.cellsig.2008.08.016 |
0.121 |
|
| 2015 |
Narasimhan K, Lambert SA, Yang AW, Riddell J, Mnaimneh S, Zheng H, Albu M, Najafabadi HS, Reece-Hoyes JS, Fuxman Bass JI, Walhout AJ, Weirauch MT, Hughes TR. Mapping and analysis of Caenorhabditis elegans transcription factor sequence specificities. Elife. 4. PMID 25905672 DOI: 10.7554/eLife.06967 |
0.12 |
|
| 2004 |
Grigull J, Mnaimneh S, Pootoolal J, Robinson MD, Hughes TR. Genome-wide analysis of mRNA stability using transcription inhibitors and microarrays reveals posttranscriptional control of ribosome biogenesis factors. Molecular and Cellular Biology. 24: 5534-47. PMID 15169913 DOI: 10.1128/Mcb.24.12.5534-5547.2004 |
0.12 |
|
| 2024 |
Ostovaneh MR, Hughes TM, Wu CO, McClelland RL, Casanova R, Bluemke DA, Tracy RP, Shea S, Heckbert SR, Lima JAC, Ambale-Venkatesh B. Deep phenotyping of dementia in a multi-ethnic cardiovascular cohort: The Multi-Ethnic Study of Atherosclerosis (MESA). Plos One. 19: e0298952. PMID 38635767 DOI: 10.1371/journal.pone.0298952 |
0.12 |
|
| 2024 |
Michael YL, Senerat AM, Buxbaum C, Ezeanyagu U, Hughes TM, Hayden KM, Langmuir J, Besser LM, Sánchez B, Hirsch JA. Systematic Review of Longitudinal Evidence and Methodologies for Research on Neighborhood Characteristics and Brain Health. Public Health Reviews. 45: 1606677. PMID 38596450 DOI: 10.3389/phrs.2024.1606677 |
0.12 |
|
| 2000 |
Granger RL, Hughes TR, Ramji DP. Gene, stimulus and cell-type specific regulation of activator protein-1 in mesangial cells by lipopolysaccharide and cytokines Biochimica Et Biophysica Acta - Gene Structure and Expression. 1492: 100-107. PMID 10858536 DOI: 10.1016/S0167-4781(00)00089-0 |
0.12 |
|
| 2021 |
Shkurin A, Hughes TR. Known sequence features can explain half of all human gene ends. Nar Genomics and Bioinformatics. 3: lqab042. PMID 34104882 DOI: 10.1093/nargab/lqab042 |
0.119 |
|
| 2006 |
Donev RM, Cole DS, Sivasankar B, Hughes TR, Morgan BP. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59. Cancer Research. 66: 2451-8. PMID 16489052 DOI: 10.1158/0008-5472.CAN-05-3191 |
0.119 |
|
| 2012 |
Blake SJ, Hughes TP, Lyons AB. Drug-interaction studies evaluating T-cell proliferation reveal distinct activity of dasatinib and imatinib in combination with cyclosporine A. Experimental Hematology. 40: 612-21.e6. PMID 22521768 DOI: 10.1016/j.exphem.2012.04.003 |
0.119 |
|
| 2010 |
Weirauch MT, Hughes TR. Conserved expression without conserved regulatory sequence: the more things change, the more they stay the same. Trends in Genetics : Tig. 26: 66-74. PMID 20083321 DOI: 10.1016/j.tig.2009.12.002 |
0.119 |
|
| 2008 |
Peña-Castillo L, Tasan M, Myers CL, Lee H, Joshi T, Zhang C, Guan Y, Leone M, Pagnani A, Kim WK, Krumpelman C, Tian W, Obozinski G, Qi Y, Mostafavi S, ... ... Hughes TR, et al. A critical assessment of Mus musculus gene function prediction using integrated genomic evidence. Genome Biology. 9: S2. PMID 18613946 DOI: 10.1186/Gb-2008-9-S1-S2 |
0.119 |
|
| 2015 |
Kohlhapp FJ, Broucek JR, Hughes T, Huelsmann EJ, Lusciks J, Zayas JP, Dolubizno H, Fleetwood VA, Grin A, Hill GE, Poshepny JL, Nabatiyan A, Ruby CE, Snook JD, Rudra JS, et al. NK cells and CD8+ T cells cooperate to improve therapeutic responses in melanoma treated with interleukin-2 (IL-2) and CTLA-4 blockade. Journal For Immunotherapy of Cancer. 3: 18. PMID 25992289 DOI: 10.1186/S40425-015-0063-3 |
0.118 |
|
| 2023 |
Shkurin A, Pour SE, Hughes TR. Known sequence features explain half of all human gene ends. Nar Genomics and Bioinformatics. 5: lqad031. PMID 37035540 DOI: 10.1093/nargab/lqad031 |
0.118 |
|
| 2007 |
Walker E, Ohishi M, Davey RE, Zhang W, Cassar PA, Tanaka TS, Der SD, Morris Q, Hughes TR, Zandstra PW, Stanford WL. Prediction and testing of novel transcriptional networks regulating embryonic stem cell self-renewal and commitment. Cell Stem Cell. 1: 71-86. PMID 18371337 DOI: 10.1016/J.Stem.2007.04.002 |
0.118 |
|
| 2017 |
Heatley SL, Sadras T, Kok CH, Nievergall E, Quek K, Dang P, McClure B, Venn N, Moore S, Suttle J, Law T, Ng A, Muskovic W, Norris MD, Revesz T, ... ... Hughes TP, et al. High prevalence of relapse in children with Philadelphia-like acute lymphoblastic leukemia despite risk-adapted treatment. Haematologica. PMID 28935844 DOI: 10.3324/Haematol.2016.162925 |
0.118 |
|
| 2013 |
van Bakel H, Tsui K, Gebbia M, Mnaimneh S, Hughes TR, Nislow C. A compendium of nucleosome and transcript profiles reveals determinants of chromatin architecture and transcription. Plos Genetics. 9: e1003479. PMID 23658529 DOI: 10.1371/Journal.Pgen.1003479 |
0.118 |
|
| 2007 |
Babak T, Blencowe BJ, Hughes TR. Considerations in the identification of functional RNA structural elements in genomic alignments. Bmc Bioinformatics. 8: 33. PMID 17263882 DOI: 10.1186/1471-2105-8-33 |
0.117 |
|
| 1995 |
Henderson GB, Hughes TR, Saxena M. Distinct systems mediate the unidirectional efflux of methotrexate and cholate in human CCRF-CEM cells. Archives of Biochemistry and Biophysics. 316: 77-82. PMID 7840681 DOI: 10.1006/ABBI.1995.1012 |
0.117 |
|
| 2015 |
Zhao M, Cai C, Zhai J, Lin F, Li L, Shreve J, Thimmapuram J, Hughes TJ, Meyers BC, Ma J. Coordination of microRNAs, phasiRNAs, and NB-LRR genes in response to a plant pathogen: Insights from analyses of a set of soybean rps gene near-isogenic lines Plant Genome. 8. DOI: 10.3835/Plantgenome2014.09.0044 |
0.117 |
|
| 1996 |
Maghsoudlou SS, Hughes TR, Hornsby PJ. Analysis of the distal 5' region of the human CYP17 gene. Genome. 38: 845-9. PMID 8536998 DOI: 10.1139/g95-111 |
0.116 |
|
| 2002 |
Hughes TR, Tengku-Muhammad TS, Irvine SA, Ramji DP. A novel role of Sp1 and Sp3 in the interferon-γ-mediated suppression of macrophage lipoprotein lipase gene transcription Journal of Biological Chemistry. 277: 11097-11106. PMID 11796707 DOI: 10.1074/jbc.M106774200 |
0.116 |
|
| 2010 |
Gray LC, Hughes TR, Van den Berg CW. Binding of human antigen R (HuR) to an AU-rich element (ARE) in the 3′untranslated region (3′UTR) reduces the expression of decay accelerating factor (DAF) Molecular Immunology. 47: 2545-2551. PMID 20692039 DOI: 10.1016/j.molimm.2010.07.002 |
0.116 |
|
| 2015 |
Ross DM, Hughes TP. Discontinuation of therapy and treatment-free remission in CML Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia. 183-193. DOI: 10.1007/978-4-431-55714-2_12 |
0.116 |
|
| 2021 |
Al-Ahmadi W, Webberley TS, Joseph A, Harris F, Chan YH, Alotibi R, Williams JO, Alahmadi A, Decker T, Hughes TR, Ramji DP. Pro-atherogenic actions of signal transducer and activator of transcription 1 serine 727 phosphorylation in LDL receptor deficient mice via modulation of plaque inflammation. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 35: e21892. PMID 34569651 DOI: 10.1096/fj.202100571RR |
0.115 |
|
| 2022 |
Song J, Nabeel-Shah S, Pu S, Lee H, Braunschweig U, Ni Z, Ahmed N, Marcon E, Zhong G, Ray D, Ha KCH, Guo X, Zhang Z, Hughes TR, Blencowe BJ, et al. Regulation of alternative polyadenylation by the C2H2-zinc-finger protein Sp1. Molecular Cell. PMID 35914531 DOI: 10.1016/j.molcel.2022.06.031 |
0.114 |
|
| 2014 |
Weirauch MT, Yang A, Albu M, Cote AG, Montenegro-Montero A, Drewe P, Najafabadi HS, Lambert SA, Mann I, Cook K, Zheng H, Goity A, van Bakel H, Lozano JC, Galli M, ... ... Hughes TR, et al. Determination and inference of eukaryotic transcription factor sequence specificity. Cell. 158: 1431-43. PMID 25215497 DOI: 10.1016/J.Cell.2014.08.009 |
0.114 |
|
| 2020 |
McClure BJ, Heatley SL, Rehn J, Breen J, Sutton R, Hughes TP, Suppiah R, Revesz T, Osborn M, White D, Yeung DT, White DL. High-risk B-cell acute lymphoblastic leukaemia presenting with hypereosinophilia and acquiring a novel PAX5 fusion on relapse. British Journal of Haematology. PMID 32731299 DOI: 10.1111/bjh.17002 |
0.114 |
|
| 2000 |
Tengku-Muhammad TS, Hughes TR, Foka P, Cryer A, Ramji DP. Cytokine-mediated differential regulation of macrophage activator protein-1 genes Cytokine. 12: 720-726. PMID 10843752 DOI: 10.1006/cyto.1999.0620 |
0.114 |
|
| 2015 |
Laver JD, Li X, Ray D, Cook KB, Hahn NA, Nabeel-Shah S, Kekis M, Luo H, Marsolais AJ, Fung KY, Hughes TR, Westwood JT, Sidhu SS, Morris Q, Lipshitz HD, et al. Brain tumor is a sequence-specific RNA-binding protein that directs maternal mRNA clearance during the Drosophila maternal-to-zygotic transition. Genome Biology. 16: 94. PMID 25962635 DOI: 10.1186/S13059-015-0659-4 |
0.113 |
|
| 2021 |
Moss JWE, Williams JO, Al-Ahmadi W, O'Morain V, Chan YH, Hughes TR, Menendez-Gonzalez JB, Almotiri A, Plummer SF, Rodrigues NP, Michael DR, Ramji DP. Protective effects of a unique combination of nutritionally active ingredients on risk factors and gene expression associated with atherosclerosis in C57BL/6J mice fed a high fat diet. Food & Function. 12: 3657-3671. PMID 33900312 DOI: 10.1039/d0fo02867c |
0.113 |
|
| 2010 |
Tillo D, Kaplan N, Moore IK, Fondufe-Mittendorf Y, Gossett AJ, Field Y, Lieb JD, Widom J, Segal E, Hughes TR. High nucleosome occupancy is encoded at human regulatory sequences. Plos One. 5: e9129. PMID 20161746 DOI: 10.1371/Journal.Pone.0009129 |
0.113 |
|
| 2018 |
McClure BJ, Heatley SL, Kok CH, Sadras T, An J, Hughes TP, Lock RB, Yeung D, Sutton R, White DL. Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expression. British Journal of Cancer. PMID 29531323 DOI: 10.1038/s41416-018-0022-0 |
0.113 |
|
| 2015 |
Hayes J, Thygesen H, Droop A, Hughes TA, Westhead D, Lawler SE, Wurdak H, Short SC. Prognostic microRNAs in high-grade glioma reveal a link to oligodendrocyte precursor differentiation. Oncoscience. 2: 252-62. PMID 25897422 DOI: 10.18632/oncoscience.112 |
0.113 |
|
| 2020 |
Chakraborti S, Balakrishnan D, Trotter AJ, Gittens WH, Yang AWH, Jolma A, Paterson JR, Świątek S, Plewka J, Curtis FA, Bowers LY, Pålsson LO, Hughes TR, Taube M, Kozak M, et al. A bacteriophage mimic of the bacterial nucleoid-associated protein Fis. The Biochemical Journal. PMID 32207815 DOI: 10.1042/BCJ20200146 |
0.113 |
|
| 2011 |
Morris Q, Bulyk ML, Hughes TR. Jury remains out on simple models of transcription factor specificity. Nature Biotechnology. 29: 483-4. PMID 21654663 DOI: 10.1038/Nbt.1892 |
0.112 |
|
| 2009 |
Alleyne TM, Peña-Castillo L, Badis G, Talukder S, Berger MF, Gehrke AR, Philippakis AA, Bulyk ML, Morris QD, Hughes TR. Predicting the binding preference of transcription factors to individual DNA k-mers. Bioinformatics (Oxford, England). 25: 1012-8. PMID 19088121 DOI: 10.1093/Bioinformatics/Btn645 |
0.112 |
|
| 2013 |
Weirauch MT, Cote A, Norel R, Annala M, Zhao Y, Riley TR, Saez-Rodriguez J, Cokelaer T, Vedenko A, Talukder S, Bussemaker HJ, Morris QD, Bulyk ML, Stolovitzky G, ... Hughes TR, et al. Evaluation of methods for modeling transcription factor sequence specificity. Nature Biotechnology. 31: 126-34. PMID 23354101 DOI: 10.1038/Nbt.2486 |
0.112 |
|
| 2023 |
Bateman JR, Krishnamurthy S, Quillen EE, Waugh CE, Kershaw KN, Lockhart SN, Hughes TM, Seeman TE, Cole SW, Craft S. Social genomics, cognition, and well-being during the COVID-19 pandemic. Medrxiv : the Preprint Server For Health Sciences. PMID 37333113 DOI: 10.1101/2023.05.31.23290618 |
0.112 |
|
| 2014 |
Sullivan AM, Arsovski AA, Lempe J, Bubb KL, Weirauch MT, Sabo PJ, Sandstrom R, Thurman RE, Neph S, Reynolds AP, Stergachis AB, Vernot B, Johnson AK, Haugen E, Sullivan ST, ... ... Hughes TR, et al. Mapping and dynamics of regulatory DNA and transcription factor networks in A. thaliana. Cell Reports. 8: 2015-30. PMID 25220462 DOI: 10.1016/J.Celrep.2014.08.019 |
0.111 |
|
| 2003 |
Krogan NJ, Keogh MC, Datta N, Sawa C, Ryan OW, Ding H, Haw RA, Pootoolal J, Tong A, Canadien V, Richards DP, Wu X, Emili A, Hughes TR, Buratowski S, et al. A Snf2 family ATPase complex required for recruitment of the histone H2A variant Htz1. Molecular Cell. 12: 1565-76. PMID 14690608 DOI: 10.1016/S1097-2765(03)00497-0 |
0.111 |
|
| 2016 |
Solana J, Irimia M, Ayoub S, Orejuela MR, Zywitza V, Jens M, Tapial J, Ray D, Morris Q, Hughes TR, Blencowe BJ, Rajewsky N. Conserved functional antagonism of CELF and MBNL proteins controls stem cell-specific alternative splicing in planarians. Elife. 5. PMID 27502555 DOI: 10.7554/eLife.16797 |
0.11 |
|
| 2010 |
Beaver JE, Tasan M, Gibbons FD, Tian W, Hughes TR, Roth FP. FuncBase: a resource for quantitative gene function annotation. Bioinformatics (Oxford, England). 26: 1806-7. PMID 20495000 DOI: 10.1093/Bioinformatics/Btq265 |
0.11 |
|
| 2005 |
Ingvarsdottir K, Krogan NJ, Emre NC, Wyce A, Thompson NJ, Emili A, Hughes TR, Greenblatt JF, Berger SL. H2B ubiquitin protease Ubp8 and Sgf11 constitute a discrete functional module within the Saccharomyces cerevisiae SAGA complex. Molecular and Cellular Biology. 25: 1162-72. PMID 15657441 DOI: 10.1128/Mcb.25.3.1162-1172.2005 |
0.11 |
|
| 2021 |
Szabo A, Akkouh IA, Vandenberghe M, Osete JR, Hughes T, Heine V, Smeland OB, Glover JC, Andreassen OA, Djurovic S. A human iPSC-astroglia neurodevelopmental model reveals divergent transcriptomic patterns in schizophrenia. Translational Psychiatry. 11: 554. PMID 34716291 DOI: 10.1038/s41398-021-01681-4 |
0.11 |
|
| 2015 |
Taylor JJ, Larrew T, Omole A, Roberts M, Kornegay A, Kornegay K, Yamada L, Revuelta GJ, Sohn M, Hughes T, Edwards JC. The feasibility of establishing a free clinic for uninsured patients with neurologic disorders Neurology: Clinical Practice. 5: 302-308. DOI: 10.1212/CPJ.0000000000000154 |
0.11 |
|
| 1997 |
Lingner J, Hughes TR, Shevchenko A, Mann M, Lundblad V, Cech TR. Reverse transcriptase motifs in the catalytic subunit of telomerase. Science (New York, N.Y.). 276: 561-7. PMID 9110970 DOI: 10.1126/Science.276.5312.561 |
0.109 |
|
| 2021 |
El Khawanky N, Hughes A, Yu W, Myburgh R, Matschulla T, Taromi S, Aumann K, Clarson J, Vinnakota JM, Shoumariyeh K, Miething C, Lopez AF, Brown MP, Duyster J, Hein L, ... ... Hughes TP, et al. Demethylating therapy increases anti-CD123 CAR T cell cytotoxicity against acute myeloid leukemia. Nature Communications. 12: 6436. PMID 34750374 DOI: 10.1038/s41467-021-26683-0 |
0.109 |
|
| 2013 |
Schafranek L, Leclercq TM, White DL, Hughes TP. Clarithromycin enhances dasatinib-induced cell death in chronic myeloid leukemia cells, by inhibition of late stage autophagy. Leukemia & Lymphoma. 54: 198-201. PMID 22656271 DOI: 10.3109/10428194.2012.698737 |
0.108 |
|
| 2010 |
Jolma A, Kivioja T, Toivonen J, Cheng L, Wei G, Enge M, Taipale M, Vaquerizas JM, Yan J, Sillanpää MJ, Bonke M, Palin K, Talukder S, Hughes TR, Luscombe NM, et al. Multiplexed massively parallel SELEX for characterization of human transcription factor binding specificities. Genome Research. 20: 861-73. PMID 20378718 DOI: 10.1101/Gr.100552.109 |
0.108 |
|
| 2015 |
Ding P, McFarland KA, Jin S, Tong G, Duan B, Yang A, Hughes TR, Liu J, Dove SL, Navarre WW, Xia B. A Novel AT-Rich DNA Recognition Mechanism for Bacterial Xenogeneic Silencer MvaT. Plos Pathogens. 11: e1004967. PMID 26068099 DOI: 10.1371/Journal.Ppat.1004967 |
0.107 |
|
| 2023 |
Hu X, Logan JG, Kwon Y, Lima JAC, Jacobs DR, Duprez D, Brumback L, Taylor KD, Durda P, Johnson WC, Cornell E, Guo X, Liu Y, Tracy RP, Blackwell TW, ... ... Hughes TM, et al. Multi-ancestry epigenome-wide analyses identify methylated sites associated with aortic augmentation index in TOPMed MESA. Scientific Reports. 13: 17680. PMID 37848499 DOI: 10.1038/s41598-023-44806-z |
0.107 |
|
| 2006 |
Alexandrov A, Chernyakov I, Gu W, Hiley SL, Hughes TR, Grayhack EJ, Phizicky EM. Rapid tRNA decay can result from lack of nonessential modifications. Molecular Cell. 21: 87-96. PMID 16387656 DOI: 10.1016/J.Molcel.2005.10.036 |
0.107 |
|
| 2021 |
Patel ZM, Hughes TR. Global properties of regulatory sequences are predicted by transcription factor recognition mechanisms. Genome Biology. 22: 285. PMID 34620190 DOI: 10.1186/s13059-021-02503-y |
0.106 |
|
| 2023 |
Manichaikul A, Hu X, Logan J, Kwon Y, Lima J, Jacobs D, Duprez D, Brumback L, Taylor K, Durda P, Johnson C, Cornell E, Guo X, Liu Y, Tracy R, ... ... Hughes T, et al. Multi-ancestry epigenome-wide analyses identify methylated sites associated with aortic augmentation index in TOPMed MESA. Research Square. PMID 37502922 DOI: 10.21203/rs.3.rs-3125948/v1 |
0.106 |
|
| 2012 |
Yin OQ, Giles FJ, Baccarani M, le Coutre P, Chiparus O, Gallagher N, Saglio G, Hughes TP, Hochhaus A, Kantarjian HM, Larson RA. Concurrent use of proton pump inhibitors or H2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology. 70: 345-50. PMID 22623211 DOI: 10.1007/s00280-012-1881-3 |
0.106 |
|
| 2017 |
Han H, Braunschweig U, Gonatopoulos-Pournatzis T, Weatheritt RJ, Hirsch CL, Ha KC, Radovani E, Nabeel-Shah S, Sterne-Weiler T, Wang J, O'Hanlon D, Pan Q, Ray D, Zheng H, Vizeacoumar F, ... ... Hughes TR, et al. Multilayered Control of Alternative Splicing Regulatory Networks by Transcription Factors. Molecular Cell. 65: 539-553.e7. PMID 28157508 DOI: 10.1016/J.Molcel.2017.01.011 |
0.106 |
|
| 1996 |
Nugent CI, Hughes TR, Lue NF, Lundblad V. Cdc13p: A single-strand telomeric DNA-binding protein with a dual role in yeast telomere maintenance Science. 274: 249-252. PMID 8824190 DOI: 10.1126/Science.274.5285.249 |
0.106 |
|
| 2009 |
Kaplan N, Moore IK, Fondufe-Mittendorf Y, Gossett AJ, Tillo D, Field Y, LeProust EM, Hughes TR, Lieb JD, Widom J, Segal E. The DNA-encoded nucleosome organization of a eukaryotic genome. Nature. 458: 362-6. PMID 19092803 DOI: 10.1038/Nature07667 |
0.106 |
|
| 2010 |
Chowdhury S, Lloyd-Price J, Smolander OP, Baici WCV, Hughes TR, Yli-Harja O, Chua G, Ribeiro AS. Information propagation within the Genetic Network of Saccharomyces cerevisiae Bmc Systems Biology. 4. PMID 20977725 DOI: 10.1186/1752-0509-4-143 |
0.106 |
|
| 2009 |
Blencowe B, Brenner S, Hughes T, Morris Q. Post-transcriptional gene regulation: RNA-protein interactions, RNA processing, mRNA stability and localization. Pacific Symposium On Biocomputing. Pacific Symposium On Biocomputing. 545-8. PMID 19209730 |
0.106 |
|
| 2015 |
Marciano DP, Kuruvilla DS, Boregowda SV, Asteian A, Hughes TS, Garcia-Ordonez R, Corzo CA, Khan TM, Novick SJ, Park H, Kojetin DJ, Phinney DG, Bruning JB, Kamenecka TM, Griffin PR. Pharmacological repression of PPARγ promotes osteogenesis. Nature Communications. 6: 7443. PMID 26068133 DOI: 10.1038/Ncomms8443 |
0.106 |
|
| 2007 |
Huang JC, Babak T, Corson TW, Chua G, Khan S, Gallie BL, Hughes TR, Blencowe BJ, Frey BJ, Morris QD. Using expression profiling data to identify human microRNA targets. Nature Methods. 4: 1045-9. PMID 18026111 DOI: 10.1038/Nmeth1130 |
0.105 |
|
| Hide low-probability matches. |